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ABSTRACT
Environmental agents are common causes of bladder cancer. Specifically, arsenic
(As3+) and cadmium (Cd2+) are known carcinogens implicated in the development of
bladder cancer. Previous studies from our laboratory have shown that As3+ and Cd2+ can
cause malignant transformation of normal immortalized bladder urothelial cells, which
can form tumors when injected subcutaneous or intraperitoneal into nude mice.
Microarray analysis of repeated metal transformation in parallel revealed that N-cadherin
was the most upregulated gene in As3+ transformants, and a top induced gene in Cd2+transformed cells. The switch from E-cadherin to N-cadherin is a well-known indicator of
the epithelial-to-mesenchymal transition occurring in bladder cancer. Further, N-cadherin
upregulation is correlated with tumor stage, increased recurrence, and decreased survival
in patients. While the factors mediating the decrease in E-cadherin expression are wellestablished, little is known of the factors regulating the increase in N-cadherin
expression. The goal of the present study was to determine how As3+ and Cd2+ regulate
N-cadherin expression, whether this expression is maintained in heterotransplant models,
and if N-cadherin is promoting the epithelial-to-mesenchymal transition in As3+- and
Cd2+-transformed UROtsa cells in vitro. This work has demonstrated that N-cadherin is
induced in As3+- and Cd2+-transformed UROtsa cell lines, and that the expression is
maintained in intraperitoneal, but not subcutaneous, tumor xenografts. Further, tumorinitiating cells derived from transformed UROtsa cells did not express N-cadherin. This

xiv

suggests that tumor microenvironment and heterogeneity of cell populations are
important factors for the use of animal models in cancer research. The As3+ and Cd2+
UROtsa cell lines represent the initial phases of EMT in bladder cancer, and may
demonstrate a unique EMT pathway specific to heavy metal carcinogens. Transcriptional
regulation of N-cadherin, which is mostly unknown, may be elucidated by the
investigation of the transcription factor Twist and epigenetic regulation, particularly
histone acetylation.

xv

CHAPTER I
INTRODUCTION
Environmental Background in Bladder Cancer
The first link between environmental agents and bladder cancer was discovered
by Ludwig Rehn in1895, in which he found an increased incidence of bladder cancer in
workers using aniline at a dye manufacturer in Frankfurt, Germany (Dietrich & Dietrich,
2001; Rehn, 1895). The findings of Rehn initiated the study of occupational bladder
carcinogens and spurred the development of occupational toxicology. Later in 1937, 2naphthylamine, an aromatic amine, was found to be the bladder cancer-causing agent
(Hueper, Wiley, & Wolfe, 1938). By the 1950’s, subsequent studies of industrial workers
lead to the discovery of multiple other aromatic amines which cause bladder cancer.
Exposure to carcinogenic aromatic amines was found in the rubber, textile, and chemical
industries (Johansson & Cohen, 1997).
Slowly, regulations were instituted which have limited occupational exposure to
these bladder carcinogens. With this reduction, cigarette smoking is now the main cause
of bladder cancer in the United States (Freedman, Silverman, Hollenbeck, Schatzkin, &
Abnet, 2011). There is an approximately 3 times higher risk for bladder cancer in
smokers versus non-smokers (Zeegers, Tan, Dorant, & Van Den Brandt, 2000). While the
precise mechanism is unclear, aromatic amines, unsaturated aldehydes, and cadmium in
cigarettes are known carcinogens (Johansson & Cohen, 1997; Vineis & Pirastu, 1997).
Smokers are exposed to 1.7 µg cadmium per cigarette, and have double the body burden
1

of cadmium compared to non-smokers (ATSDR, 2012). Cigarettes also contain arsenic at
levels up to 1.4 µg per cigarette (C. Smith, Livingston, & Doolittle, 1997).
Bladder cancer due to arsenic exposure was initially discovered in Taiwan, where
residents drank water from artesian wells containing high amounts of the metal. Arsenicinduced bladder cancer has been confirmed by a number of studies since then.
Evidence of bladder carcinogenesis due to cadmium exposure is seen in Belgium,
where increasing levels of blood cadmium were correlated with cancer risk (Kellen,
Zeegers, Hond, & Buntinx, 2007). However, the evidence for cadmium-induced bladder
cancer is less than that of arsenic.
Chronic infection with the parasite Schistosoma haematobium is also known to
cause bladder cancer, predominantly squamous cell carcinoma (Mostafa, Sheweita, &
O’Connor, 1999). Chronic infections in addition to that of Schistosoma haematobium
may also promote bladder cancer, though direct links have yet to be proven (Abol-Enein,
2008).
Arsenic Causes Bladder Cancer
The general public is exposed to arsenic primarily by the oral route through food and
drinking water (ATSDR, 2007). Oral ingestion of inorganic arsenic is known to cause
skin, kidney, liver, lung, and prostate cancer in addition to that of bladder. Average
dietary consumption of inorganic arsenic in the United States is 10.22 µg/day (MacIntosh
et al., 1997), while exposure through drinking water is about 5 µg/day (ATSDR, 2007).
The current limit of arsenic in drinking water is 10 ppb (EPA, 2001). Arsenic can leach
from the soil into ground and surface water. Releases into the environment are mainly
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from anthropogenic sources including nonferrous metal mining and smelting, pesticide
use, coal and wood combustion, and waste combustion (ATSDR, 2007).
Evidence of Arsenic Carcinogenicity
Numerous epidemiological studies have proven the link between arsenic and bladder
cancer. The discovery of arsenic-induced bladder cancer in Taiwan was initiated by the
high incidence of blackfoot disease, a peripheral artery disease caused by arsenic
exposure (Tseng, 1977). Upon investigation of these blackfoot-endemic regions, it was
found that residents of this area also had high rates of bladder cancer (C. J. Chen,
Chuang, Lin, & Wu, 1985). High exposure to arsenic in drinking water was later
confirmed as the cause of bladder cancer in this region.
Following initial reports of increased bladder cancer in Taiwan (C J Chen, Chen, Wu,
& Kuo, 1992; C J Chen, Chuang, You, Lin, & Wu, 1986; C. J. Chen et al., 1985; C. J.
Chen & Wang, 1990; Chiou et al., 1995; L. Wang et al., 2012), evidence arose of bladder
cancer due to arsenic in drinking water in Argentina (Hopenhayn-Rich et al., 1996) and
Chile (A. H. Smith, Goycolea, Haque, & Biggs, 1998). More recent studies have shown
links between arsenic in drinking water and bladder cancer in Tunisia (Feki-Tounsi et al.,
2013b) and Pakistan (Wadhwa, Kazi, Afridi, Tüzen, & Citak, 2013). Studies of bladder
cancer in Chile show that the effects of arsenic exposure have a long latency period, as
increased bladder cancer mortality rates did not appear until 10 years following exposure
to arsenic-contaminated drinking water (Marshall et al., 2007). Even 40 years later,
bladder cancer odds ratios were elevated compared to the general population (Steinmaus
et al., 2013). In Taiwan, studies report reduced bladder cancer incidence and mortality
only after twenty years of exposure cessation through installation of tap water systems
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(C.-C. Su, Lu, Tsai, & Lian, 2011; C.-Y. Yang, Chiu, Chang, Ho, & Wu, 2005), though
rates remained elevated compared to the general population.
Epidemiological studies have been performed in the United States to determine if
bladder cancer rates in Taiwan and other countries may be used to extrapolate risk at
lower concentrations typically seen in the United States, as well as in populations of
differing ethnicity. Previous studies showed increased bladder cancer risk at exposures
over 300 mg/L (C. Chen et al., 2009; Chiou et al., 1995) Studies in Utah, Michigan, and
Idaho with arsenic concentrations of 0-166 µg/L in drinking water found no change in
bladder cancer risk, incidence, or mortality rates (Han, Weissfeld, Davis, & Talbott,
2009; Lewis, Southwick, Ouellet-Hellstrom, Rench, & Calderon, 1999; Meliker et al.,
2010; Meliker, Wahl, Cameron, & Nriagu, 2007). In 2004, a nationwide study found no
correlation between arsenic exposures of 3-60 µg/L and bladder cancer mortality rates
(Lamm et al., 2004). A meta-analysis of 9 studies for bladder cancer risk also found no
significant difference, though it suggested that the influence of cigarette smoking should
be evaluated at these lower exposure levels (J. S. Tsuji, Alexander, Perez, & Mink,
2014). Finally, an epidemiological study in Taiwan that was re-evaluated to exclude high
arsenic exposures found that bladder cancer risk does not increase until 100-200 µg/L in
drinking water (Lamm et al., 2014).
Animal models of arsenic-induced bladder cancer have been difficult to replicate.
Past studies with inorganic exposure alone have not found increased incidence of bladder
tumors, except in whole-life exposure. Mice exposed to inorganic arsenic prior to
breeding, during pregnancy, lactation, and after weaning through adulthood show
increased levels of urinary hyperplasia (Tokar, Diwan, Ward, Delker, & Waalkes, 2011).
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There are mixed results with organic arsenic carcinogenicity models. Exposure to
dimethylarsenic acid for 2 years at 12.5, 50, and 200 mg/L in drinking water causes a
significant increase in bladder tumors and urothelial hyperplasia (Wei et al., 2002; Wei,
Wanibuchi, Yamamoto, Li, & Fukushima, 1999) and dietary exposure to 100 mg/L DMA
causes urothelial cell papilloma and carcinoma in rats (Arnold, Eldan, Nyska, van
Gemert, & Cohen, 2006). However, DMA in the diet does not cause cancer in mice at
exposures up to 500 ppm (Arnold et al., 2006).
There are cases in which arsenic acts as a co-carcinogen in animal models.
Gestational exposure to 85 mg/L inorganic arsenic in mice followed by postnatal
tamoxifen treatment increases formation of urinary bladder transitional cell tumors and
bladder hyperplasia compared to either treatment individually (Waalkes, Liu, Ward, &
Diwan, 2006). Increased urinary bladder proliferative lesions are also seen for
transplacental inorganic arsenic exposure followed by postnatal diethylstilbestrol
treatment (Waalkes et al., 2006). DMA treatment enhances tumor induction in
diethylnitrosamine, N-butyl-N-(4-hydroxybutyl)nitrosamine, N-methyl-N-nitrosourea,
dihydroxy-di-N-propylnitrosamine, and N-N'-dimethylhydrazine-treated rats (S.
Yamamoto et al., 1995).
Potential Mechanisms of Cancer Induction by Arsenic
The mechanism by which arsenic causes bladder cancer has yet to be elucidated. The
general theory is that inorganic arsenic undergoes metabolism to reactive metabolites
which cause cytotoxicity. In response, the urothelium undergoes regenerative
proliferation, leading to development of tumors. (Arnold et al., 2014; Cohen, Arnold,
Beck, Lewis, & Eldan, 2013). Inorganic arsenic undergoes a series of reductions and
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methylations leading to the formation of reactive metabolites including oxygenated
compounds of trivalent and pentavalent arsenic, as well as thiolated pentavalent arsenic
compounds. Inorganic pentavalent arsenate is converted to trivalent arsenite (AsIII)
mainly in the blood and liver by arsenate reductase, followed by transport into cells
(Figure 1.1). Inorganic arsenic may be transported by a number of proteins including
aquaporin (Z. Liu et al., 2002), phosphate transporters (Rosen, 2002) and glucose
transporters (Drobná et al., 2010). Inside the cell, arsenic methyltransferase converts
trivalent arsenite to pentavalent monomethylarsonic acid (MMAV). Monomethylarsonic
acid is then reduced to trivalent monomethylarsenous acid (MMAIII) by
monomethylarsonic acid reductase and oxidatively methylated by monomethylamine
methyltransferase to form dimethylarsenic acid (DMAV) (Cohen, Arnold, Eldan, Lewis,
& Beck, 2006). The liver is the main site of methylation and reduction, though arsenite
may be metabolized in other tissues (Vahter, 2002). Monomethylarsenic acid and
DMA(V) are the predominant metabolites found in the urine following inorganic arsenic
exposure (Vahter, 2002). In mice exposed to arsenate, both DMA(V) and inorganic
arsenic may be found in the urine, though DMA(V) is the major metabolite (Hughes et
al., 2003; Kenyon et al., 2008). However, humans generate more MMA(V) than other
animals (Hernández-Zavala et al., 2008). Rats metabolize DMA(V) to trimethylarsenic
oxide, while humans do not, an important factor to consider when using rats as a model
for arsenic metabolism and carcinogenesis (Cohen et al., 2006).
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Figure 1.1 Metabolism of arsenate. Adapted from (Y. Chen et al., 2003).
As(V): Arsenate, As(III): Arsenite, MMA(V): Monomethylarsonic acid, MMA(III):
Monomethylarsenous acid, DMA(V): Dimethylarsenic acid

Trivalent and pentavalent arsenicals, both organic and inorganic, are cytotoxic,
though the species differ in potency, and cytotoxicity dependent upon its concentration
and potential to react with sulfhydryl groups (Cohen et al., 2006; Yager et al., 2013).
Trivalent arsenicals are considered more toxic due to their greater transport efficiency
into the cell and enhanced binding affinity to sulfhydryl groups (Cohen et al., 2006).
Dimethylarsonous acid, DMA(V), and As(III) are the most toxic to bladder cells (Cohen
et al., 2002; Styblo et al., 2000)
The mechanisms which mediate arsenic cytotoxicity can include genotoxicity,
oxidative stress, and dysregulation of cell signaling pathways. Trivalent arsenicals bind
selectively to sulfhydryl-containing proteins including metallothionein, rat hemoglobin,
and zinc finger proteins (Demicheli et al., 2011; G. Jiang, Gong, Li, Cullen, & Le, 2003;
Kitchin & Wallace, 2008; Yan, Wang, Weinfeld, Cullen, & Le, 2009; X. Zhou et al.,
2011). The effect of this interaction on cytotoxic mechanisms therefore is dependent
upon cell type and arsenic species (Cohen et al., 2013).
While arsenic is not mutagenic, it causes genotoxicity through inhibition of DNA
repair systems or the generation of reactive oxygen species (ROS) that are damaging to
DNA (Klein, Leszczynska, Hickey, & Rossman, 2007; Nesnow et al., 2002). Methylated
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arsenic metabolites interact with zinc finger proteins involved in DNA repair and damage
signaling, inhibiting base excision repair and nucleotide excision repair (Hartwig et al.,
2002). Further, arsenic-induced bladder cancer risk is increased in individuals with a
variant of XRCC3, a double-strand break repair gene (Andrew et al., 2009). DNA
damage induced by MMA(III) and DMA(III) is prevented by treatment with ROS
inhibitors Tiron, melatonin, and the vitamin E analog Trolox (Nesnow et al., 2002).
Oxidative stress due to arsenic exposure is damaging to lipids and proteins, in
addition to DNA. Trivalent arsenicals, particularly DMA(III), cause lipid peroxidation
and the protein oxidation in vitro (Shi, Shi, & Liu, 2004; T.-C. Wang, Jan, Wang, &
Gurr, 2007). Sodium arsenite and MMA(III) induce ROS in the immortalized human
urothelial cell line UROtsa which is reverted by catalase or superoxide dismutase.
Oxidative DNA damage is observed, as well as induction of Hsp70 and metallothionein,
a protein which protects the cell against metal toxicity and oxidative stress (Eblin et al.,
2006; Michael R Rossi et al., 2002). Glutathione is a major antioxidant of the cell
(Forman, Zhang, & Rinna, 2009), and is the electron donor for the reduction of arsenate
to arsenite (Scott, Hatlelid, MacKenzie, & Carter, 1993). A decrease in glutathione and
an increase of glutathione disulfide, the oxidized peptide created during ROS
detoxification, is an indicator of chronic oxidative stress (Lu, 2009). Glutathione is a
tripeptide containing a cysteine residue available for arsenite binding (Scott et al., 1993).
In mice and humans exposed to arsenic-containing water for prolonged periods, liver
glutathione is decreased, accompanied by an induction in glutathione disulfide (Hall et
al., 2013; Santra, Maiti, Chowdhury, & Mazumder, 2000). Low arsenite exposure in
UROtsa cells stimulates an accumulation of ubiquitin-conjugated protein that is increased
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upon reduction of cellular glutathione, suggesting that glutathione may prevent disruption
of the ubiquitin-proteasome pathway caused by arsenic (Bredfeldt, Kopplin, & Gandolfi,
2004). Thioredoxin, an electron donor for the reduction of MMA(V) to MMA(III), is also
an important cell antioxidant (Kitchin & Wallace, 2008). Thioredoxin activity is
decreased following As(III) and MMA(V) exposure in hepatocytes (S. Lin et al., 2001),
which may mediate arsenic-induced apoptosis (Arnér & Holmgren, 2000; Shi et al.,
2004).
Several epigenetic modifications are altered in arsenic-induced carcinogenesis,
including DNA methylation and histone acetylation, to enhance expression of tumorpromoting genes. It is believed that methylation during arsenic biotransformation by
arsenic methyltransferase depletes availability of the methyl donor S-adenosyl
methionine (SAM), reducing DNA methylation activity to cause a global hypomethylated
state (Bustaffa, Stoccoro, Bianchi, & Migliore, 2014). However, while hypomethylation
is a prominent global characteristic of arsenic transformation, many cell types and
specific genes do not demonstrate hypomethylation, including UROtsa cells transformed
with MMA(V). This study found that alterations in DNA methylation occurr nonrandomly at hundreds of gene promoters to alter gene expression. Further, the DNA
methylation changes are permanent, as removal of arsenic does not alter DNA
methylation levels, gene expression, or malignant phenotype (Jensen, Novak, Wnek,
Gandolfi, & Futscher, 2009).
Urothelial cancers from arsenic-contaminated areas show gene-specific
hypermethylation of death-associated protein kinase (DAPK), a member of the apoptosis
pathway downstream of interferon-γ, TNF-α, and Fas signaling. Hypermethylation of the
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DAPK promoter is correlated with tumor invasiveness, grade, and recurrence.
Hypermethylation of the DAPK promoter is associated with decreased expression (W. T.
Chen, Hung, Kang, Huang, & Chai, 2007). In SV-HUC-1 cells exposed to sodium
arsenite, promoter hypermethylation of the tumor suppressor RECK leads to decreased
expression of the gene, a tumor invasion and angiogenesis suppressor (Y. Huang, Hung,
Chen, Yu, & Chai, 2011). Urothelial cancers from blackfoot disease-endemic areas also
show decreased RECK protein levels compared to cancers from non-endemic regions (Y.
C. Huang et al., 2011). Additionally, urothelial carcinomas from a blackfoot disease area
show elevated expression of cyclin D1 that is confirmed in arsenite-treated SV-HUC-1
cells. Further, cyclin D1 expression is dependent upon DNA methylation state (Y. C.
Huang et al., 2011). Hypermethylation of the CTBP1 promoter has been observed in
HUC-1 cells exposed to transforming levels of sodium arsenite, accompanied by
increased expression of the gene which is involved in regulation of epithelial phenotype
(Grooteclaes & Frisch, 2000; Michailidi et al., 2015; Peinado, Olmeda, & Cano, 2007).
Conversely, arsenite causes hypermethylation of the HER2 and NFĸB2 promoters,
increasing gene expression (Michailidi et al., 2015). In another study, chronic sodium
arsenite exposure to immortalized human urothelial cells causes hypomethylation and
overexpression of lipocalin-2, an oncogene that promotes metastasis through the
LCN2/MMP9 complex and enhancement of the epithelial-to-mesenchymal transition (H.
H. Wang et al., 2014).
Assessment of the histone acetylation state of 13,000 promoters in arsenitetransformed UROtsa cells and normal UROtsa cells exposed to transforming levels of
MMA(III) reveals changes in histone H3 acetylation, which enhances DNA
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hypermethylation at these regions to alter the expression state of the associated gene
(Jensen, Novak, Eblin, Gandolfi, & Futscher, 2008).
Alterations in histone acetylation are also believed to promote carcinogenesis in
bladder (Bustaffa et al., 2014). Quantitative mass spectrometric analysis of histone
epigenetic state following arsenite or MMA(III) exposure to UROtsa cells discovered a
global decrease in acetylation at several H3 and H4 lysine residues (Chu et al., 2011).
MYST1, a histone 4 lysine 16 acetyltransferase plays a role in urothelial resistance to
arsenic cytotoxicity. UROtsa cells lacking the MYST1 gene show increased sensitivity to
arsenite and MMA(III), along with dose- and time-dependent decreases in global H4K16
acetylation (Jo et al., 2009). In another study, low level MMA(III) exposure increases
expression and activity of histone deacetylases, leading to reduced global histone
acetylation in UROtsa cells (Ge et al., 2013).
In a review of genomic dose-response information in models of arsenic
carcinogenesis, common pathways altered by chronic low exposure include oxidative
stress, proteotoxicity, inflammation, proliferative signaling, DNA repair, cell cycle G2/M
checkpoint control, and induction of apoptosis (Xie et al., 2010). The arsenic-transformed
UROtsa cells demonstrate permanent induction of pathways involved in mismatch repair,
amino acid metabolism, glycolysis/gluconeogenesis and alkaloid biosynthesis and
repression of apoptosis and endocytosis pathways (unpublished data). Global gene
expression analysis has also been performed on 1T1 bladder cells exposed to As(III),
MMA(III), and DMA(III) for 24 hrs. Among all arsenicals, the NRF2-mediated oxidative
stress response, cholesterol biosynthesis, and interleukin-10 signaling pathways are
altered (Dodmane et al., 2013). Indeed, NRF2-repressed UROtsa cells demonstrate
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increased sensitivity to sodium arsenite and MMA(III), while NRF2 overexpression
promotes a tolerance to arsenic cytotoxicity (X.-J. Wang et al., 2007). In another study of
As(III) and MMA(III) treated cells, the p53 signaling pathway is deregulated in both
treatments, while changes in cell cycle regulation and DNA damage response are unique
to As(III) exposure (Dodmane et al., 2013). UROtsa cells exposed to 50 nM MMA(III)
are malignantly transformed after 3 months. While subtle changes in gene expression
occurr over the first 2 months, the same pathways are substantially altered at 3 months.
These include oxidative stress, cell proliferation, anti-apoptosis, MAPK and
inflammation pathways (Medeiros et al., 2012).
Proteomic analysis of primary and immortalized uroepithelial cells treated with
arsenite trioxide for 3 weeks shows alterations in proteins involved with nucleotide
binding, lipid metabolism, protein folding, biosynthesis, transcription, DNA repair, cell
cycle control, and signal transduction (S. Chen et al., 2010). Genomic analysis of mouse
urine exposed to arsenate in drinking water for up to 12 weeks discovered enhanced
epithelial-to-mesenchymal transition, inflammation, and proliferation pathways, while in
a study of rat urothelium after exposure to DMA(III) for 28 days, changes were seen in
genes for apoptosis, cell cycle regulation, oxidative stress response, and cancer control
processes (Clewell et al., 2011; Sen, Wang, Hester, Robertson, & Wolf, 2005).
Cadmium Causes Bladder Cancer
Cadmium was demonstrated to have negative consequences for human health in
1955, when outbreaks in Japan of Itai-Itai disease, translated as “it hurts-it hurts”, were
linked to cadmium exposure. Releases of cadmium effluent from a nearby zinc mine
contaminated rice paddies, which provided the main source of food for residents in the
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area. Toxicity is characterized by renal injury due to tubular and glomerular dysfunction
and bone injury consisting of osteomalacia and osteoporosis. Initial femoral pain spreads
throughout the body, ultimately causing the patient to become bed-ridden (Inaba et al.,
2005).
Exposure to cadmium in humans is mainly through diet and cigarette smoking (NTP,
2011). The largest contribution to dietary cadmium is leafy vegetables including lettuce
and spinach, potatoes and grain, peanuts, soybeans, and sunflower seeds (ATSDR, 2012;
FDA, 2008). Liver and shellfish also contain higher levels of cadmium (ATSDR, 2012;
Satarug & Moore, 2004). Occupational exposure to cadmium may occur in zinc and iron
ore smelting, welding cadmium-coated steel, working with solders containing cadmium,
and handling or producing cadmium powders (NTP, 2011). The estimated cadmium
intake is 0.35 µg/kg/day in males and 0.30 µg/kg/day in females (Choudhury et al.,
2001). Cadmium is found in the Earth’s crust and is distributed in dust, volcanic
emissions, and forest fires along with other natural phenomena (ATSDR, 2012).
However, anthropogenic production is the main source of cadmium in the environment.
Zinc, copper, and lead smelting, coal and oil-fired broilers, and industrial waste
incinerators release cadmium into the environment. Application of phosphate fertilizers
and waste leaching from landfills also releases cadmium into the soil and water (EPA,
1985).
Evidence of Cadmium Carcinogenicity
Cadmium is classified as a carcinogen (IARC, 1993), though the evidence for bladder
cancer induction by cadmium is less than that of arsenic. In a study of bladder cancer
cases in Belgium, increasing levels of blood cadmium are correlated with bladder cancer
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risk (Kellen et al., 2007). However, a study of cancer incidence in northeastern Belgium
and southeastern Netherlands found no correlation between long-term emission of
cadmium by zinc smelters and bladder cancer incidence (Verhoeven et al., 2011). A study
of Tunisian men also found that blood cadmium levels are significantly higher in cases of
bladder cancer and that cadmium levels are correlated with smoking and age (FekiTounsi et al., 2013a). Urinary metallothionein-bound cadmium is significantly elevated in
transitional cell carcinoma patients as measured by inductively coupled plasma mass
spectrometry (Wolf, Strenziok, & Kyriakopoulos, 2009). In addition, a study based in
Montreal, Quebec, Canada implicates occupational exposure to cadmium compounds to
bladder cancer risk (Siemiatycki, Dewar, Louise, & Gérin, 1997). One difficulty in
epidemiological studies of cadmium-induced carcinogenesis is the confounding factor of
cigarette smoking. In fact, no studies have found a significant association between
cadmium and bladder cancer in non-smokers (Feki-Tounsi & Hamza-Chaffai, 2014).
Future experiments with larger sample size and non-smoking populations will help to
determine the role of cadmium in bladder cancer.
While animal studies confirm cadmium as a carcinogen, no cadmium exposure
studies have demonstrated the development of bladder cancer specifically in animals.
However, in vitro exposure to cadmium chloride malignantly transforms urothelial cells
as indicated by anchorage independent cell growth and tumor formation in nude mice
(Sens et al., 2004).
Potential Mechanisms of Cancer Induction by Cadmium
The manner by which cadmium causes bladder cancer, and all cancers in general,
remains unknown. As with arsenic-induced bladder cancer, the likely mechanism of
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cancer induction by cadmium is that of initial cytotoxicity followed by regenerative
proliferation and the development of tumors. The processes involved in each step,
however, are likely unique due to the inherent differences in cadmium and arsenic.
Changes observed during cadmium carcinogenesis include aberrant gene expression,
DNA damage repair inhibition, impairment of apoptosis, and oxidative stress (FekiTounsi & Hamza-Chaffai, 2014).
Following absorption at the small intestine, ingested cadmium accumulates
predominantly in the kidney and to a lesser extent in liver (Satarug, Baker, Reilly, Moore,
& Williams, 2002; Sumino, Hayakawa, Shibata, & Kitamura, 1975), and has a biological
half-life of at least 15-20 years (ATSDR, 2012; Jin, Lu, & Nordberg, 1998).
Metallothionein, a cysteine-rich antioxidant protein, plays an important role in cadmium
accumulation, as cadmium has the ability to bind protein thiol groups (Carballo,
Castineiras, Dominguez-Martin, Garcia-Santos, & Niclos-Gutierrez, 2013).
Metallothionein readily binds cadmium in the liver, preventing its excretion. In
metallothionein-null mice, absorption and distribution of the metal is unaffected,
however, elimination through the bile is inhibited, causing accumulation of cadmiumbound metallothionein in the body (Klaassen, Liu, & Choudhuri, 1999). Though
metallothionein accumulates cadmium in the kidney, it is protective against
nephrotoxicity. In metallothionein-null mice, renal toxicity iss enhanced compared to
controls (J. Liu, Liu, Habeebu, & Klaassen, 1998). Metallothionein expression is also
induced upon cadmium exposure in the kidney and bladder (Chung, Nartey, & Cherian,
1986; Sens et al., 2003)
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Mechanisms of cadmium transport have not been fully elucidated. Cadmium has no
known biological function and utilizes transporters for zinc, iron, and calcium. Known
cadmium transporters include divalent metal transporter 1 (SLC11A2) (Park, Cherrington,
& Klaassen, 2002), ZIP8 (SLC39A8) (Dalton et al., 2005), and ZIP14 (SLC39A14)
(Girijashanker et al., 2008). Recent studies have implicated megalin as a transporter of
cadmium-bound metallothionein (Wolff, Abouhamed, Verroust, & Thévenod, 2006).
Cadmium transport and accumulation is enhanced upon deficiency of the dietary metals
zinc, iron, and calcium (Ueda et al., 1987; Vesey, 2010), such that nutritional state must
be considered in studies of cadmium toxicity and transport.
Due to the lack of animal models, mechanisms of cadmium-induced bladder cancer
have been investigated in vitro. Inhibition of apoptosis is one manner in which cadmium
causes carcinogenesis. In normal cells, cadmium often induces apoptosis initially,
followed by resistance upon malignant transformation. Cadmium-transformed prostate
epithelial cells exhibit enhanced resistance to apoptosis induced by cadmium,
accompanied by down-regulation of several caspase family members and overexpression
of anti-apoptotic genes (W. Achanzar, Webber, & Waalkes, 2002). Cadmium exposure to
the nontransformed prostate epithelial cell line RWPE-1 induces apoptosis in 65% of
cells; however, the surviving 35% have elevated levels of metallothionein (W. E.
Achanzar, Achanzar, Lewis, Webber, & Waalkes, 2000). This suggests that
metallothionein may promote the survival of cadmium-exposed cells. Similarly, alveolar
epithelial cells subjected to repeated in vitro exposure to cadmium demonstrate increased
resistance to apoptosis caused by the oxidant hydrogen peroxide, along with elevated
expression of Metallothionein 1 and 2 (Eneman et al., 2000). Indeed, similar results are
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observed in transformation of UROtsa cells by arsenite and cadmium. The UROtsa cell
line exposed to toxic levels of sodium arsenite and cadmium chloride experience both
apoptosis and necrosis. Meanwhile, UROtsa cells malignantly transformed with arsenite
and cadmium display increased resistance to arsenite- and cadmium-induced toxicity, and
are more likely to undergo necrosis, suggesting that apoptosis inhibition may promote
heavy metal carcinogenesis. In both parent UROtsa and Cd2+-transformed cells, cadmium
exposure induce metallothionein. However, there is no difference in the level of induction
between the normal and transformed cells, indicating that metallothionein does not play a
role in arsenic or cadmium transformation (Somji, Zhou, Garrett, Sens, & Sens, 2006).
Cadmium may induce cytotoxicity and carcinogenesis by interfering with cysteinecontaining proteins such as the tumor suppressor p53. In human breast cancer MCF-7
cells, p53 induction by DNA-damaging agents is inhibited by cadmium (Méplan, Mann,
& Hainaut, 1999). While initial exposure to cadmium induces p53 expression in human
prostate epithelial cells, continued exposure reduces levels to those below baseline (W. E.
Achanzar et al., 2000).
Bladder-specific mechanisms of cadmium carcinogenesis has been investigated by
this lab in regard to aberrant gene expression. Transformation of the UROtsa cell line by
chronic cadmium exposure results in permanent induction of genes associated with
mismatch and nucleotide excision repair, DNA replication, amino acid metabolism,
glycolysis/gluconeogenesis, and sphingolipid metabolism. Repressed pathways included
apoptosis, the Jak-STAT signaling pathway, and Wnt signaling (unpublished data).
Oxidative stress has not been studied in cadmium-induced bladder cancer
specifically, but are common traits of cadmium carcinogenicity in other tissues.
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Cadmium exposure induces numerous radical species, including hydrogen peroxide,
superoxide anions, and hydroxyl anions (Bertin & Averbeck, 2006). Oxidative stress due
to cadmium has been observed both in vitro and in animal studies (Joseph et al., 2001;
Koizumi, Shirakura, Kumagai, Tatsumoto, & Suzuki, 1996; Nigam, Shukla, & Agarwal,
1999; Shih et al., 2004). In a study of the general population, urinary cadmium levels are
correlated to increased serum γ-glutamyltransferase and decreased vitamin C,
carotenoids, and vitamin E (Lee, Lim, Song, Boo, & Jacobs, 2006). However, cadmium
is not a Fenton metal, indicating that oxidative stress is generated indirectly by cadmium
(Bertin & Averbeck, 2006).
Cadmium may induce oxidative stress indirectly by reducing the levels or activity of
antioxidant enzymes, increasing the cell's vulnerability to ROS (Waisberg, Joseph, Hale,
& Beyersmann, 2003). Second, cadmium may displace iron from ferritin and apoferritin,
making iron available for ROS-producing Fenton reactions (Casalino, Sblano, &
Landriscina, 1997; Price & Joshi, 1983). Cadmium may also induce oxidative stress by
interfering with oxidative metabolism in mitochondria (Bertin & Averbeck, 2006; Nigam
et al., 1999). Cadmium-mediated oxidative stress leads to mutations and damage to DNA,
as well as lipids in several organs and cell types (Bertin & Averbeck, 2006). 8hydroxydeoxyguanosine formation, indicative of premutagenic lesions due to oxidative
stress, and DNA strand breaks are caused by cadmium exposure in HeLa and
lymphoblastoid cells (Dally & Hartwig, 1997; Mikhailova, Littlefield, Hass, Poirier, &
Chou, 1997). In addition to their damaging effects, ROS may act as signaling molecules
(Bertin & Averbeck, 2006). Reactive oxygen species generated by cadmium activates
extracellular signal-regulated kinases (ERK) and AKT to induce the pro-angiogenic
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molecule hypoxia-inducible factor-1 in human bronchial epithelial cells (Jing et al.,
2012). In BALB/c-3T3 cells transformed with cadmium chloride, ROS mediates the
upregulation of proto-oncogenes c-fos, c-jun, and c-myc (Joseph et al., 2001). The
relative importance of ROS in cadmium carcinogenesis is still unclear. In a study of rat
liver epithelial cells transformed by chronic cadmium exposure, initial induction of ROS
is abolished well before malignant transformation (Qu et al., 2005).
Cadmium may mediate carcinogenesis through the inhibition of various DNA damage
repair mechanisms, including base excision repair, nucleotide excision repair, and
mismatch repair (Giaginis, Gatzidou, & Theocharis, 2006), though alterations in these
processes have not been studied in bladder cancer specifically. Cadmium has been found
to inhibit numerous steps of base excision repair. Cadmium reduces the activity of 8oxoG glycosylase, an enzyme involved in the initiation of repair (Potts, Bespalov,
Wallace, Melamede, & Hart, 2001). It also suppresses the activity of 8-oxo-2'deoxyguanosine 5-triphosphate pyrophosphohydrolase, an enzyme which prevents
incorporation of mutagenic 8-oxo-dGTP (Bialkowski, Bialkowska, & Kasprzak, 1999).
Ape-1 endonuclease and exonuclease action is inhibited by cadmium in vitro, as well as
DNA polymerase β (Popenoe & Schmaeler, 1979) and DNA ligase 1 (McNeill,
Narayana, Wong, & Wilson, 2004; S. W. Yang, Becker, & Chan, 1996).
Studies on the effect of cadmium exposure on nucleotide excision repair reveal that
the metal inhibits initial phases of this process (Giaginis et al., 2006). Transcription factor
IIIA, an enzyme important in the initiation of nucleotide excision repair, is impaired in its
ability to bind DNA by cadmium. It is thought that cadmium binds to cysteines within the
zinc finger protein to inhibit DNA binding (Hanas & Gunn, 1996). Cadmium reduces the
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DNA binding ability of XPA, another initiator of nucleotide excision repair, likely due to
sensitivity of the zinc finger protein to cadmium (Asmuss, Mullenders, Eker, & Hartwig,
2000).
There is evidence that cadmium suppresses initial phases of mismatch repair by
inhibiting MSH2-MSH6-dependent activity, attenuating the complex’s DNA binding
affinity and reducing its ability to distinguish mismatched duplexes (Clark & Kunkel,
2004). Cadmium also inhibits DNA mismatch-repair-mediated cell cycle arrest following
alkylation damage (Lützen, Liberti, & Rasmussen, 2004). However, the mechanisms of
protein inhibition in mismatch repair does not appear to be due to the targeting of zinc
finger motifs (Giaginis et al., 2006).
Cadmium- and Arsenic-transformed UROtsa Cells
Immortalized human bladder cancer-derived cell lines are widely available and well
characterized, however, they do not allow for investigation of the initial stages of
carcinogenesis, and the cancer-inducing agent is unknown. The UROtsa cell line
originates from urothelial cells derived from the left ureter of a 12-year-old girl, which
was then immortalized with a temperature-sensitive SV40 large T-antigen gene. UROtsa
cell morphology resembls primary urothelial cells, growing in tightly packed colonies in
the shape of irregular polygonal cells with a low nucleus to cytoplasmic ratio.
Multinucleated and long fusiform cells ae observed at low frequency. The cells do not
grow in soft agar and are unable to form tumors in nude mice, indicating that they are not
neoplastically transformed. The cells were immortalized with a temperature-sensitive Tantigen such that incubation at elevated temperature would reduce growth rates, possibly
providing an in vitro model system that more closely resembled that of human

20

urothelium. The temperature-sensitive trait of the SV40 T-antigen was lost and UROtsa
cell growth rate was unchanged at elevated temperatures (Petzoldt, Leigh, Duffy, Sexton,
& Masters, 1995). Further, characterization proves that the immortalized UROtsa cell line
is a close model of normal human epithelium, with the ability to resemble the
intermediate or basal cell layer depending upon serum growth conditions.
UROtsa cells cultured on serum-containing growth medium demonstrate a basal cell
phenotype with a flattened appearance and grow as a monolayer with no tendency to
stratify. The cells have numerous desmosomal connections and moderate lateral
digitations, a high nuclear to cytoplasmic ratio, and presence of intermediate filaments.
No tight junctions nor gap junctions are observed between the apical poles of the cells.
UROtsa cells cultured on a serum-free growth medium resemble the transitional
epithelium, with multilayered formations of cells, abundant intermediate filaments, and a
more polarized epithelial morphology. The cells contain frequent desomosomal
connection and extensive interdigitation. Freeze-fracture analysis reveals the presence of
gap junctions and tight junction sealing strands between cells. The immortalized UROtsa
cell line also expresses metallothioneins and heat shock protein profiles in agreement
with in situ urothelial expression (M R Rossi et al., 2001).
This lab was the first to malignantly transform urothelial cells with cadmium and
arsenic in vitro, providing a model system for the confirmation of epidemiological studies
and further investigation of carcinogenic mechanisms and biomarker identification.
During transformation, both serum-fed and serum free cultures were used. Immortalized
UROtsa cells were fed medium containing 1 µM sodium arsenite or cadmium chloride
over a period of up to three months. Several rounds of cytotoxicity followed by regrowth
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of remaining cells occurred, after which growth rates began to increase far in excess over
the parental UROtsa cells. The transformed cells appeared morphologically similar to the
parent, though the serum-free cultures lost the ability to stratify. The transformed cells
formed colonies in soft agar, though the serum-fed cells were more efficient.
Furthermore, UROtsa cells transformed by cadmium and arsenic in serum-free media
were able to form tumors when injected subcutaneously into nude mice (Sens et al.,
2004).
The tumor heterotransplants provide a useful tool for the study of arsenic- and
cadmium-induced bladder cancer, as animal models for these cancers are difficult to
produce. The subcutaneous tumor heterotransplants generated from arsenic-transformed
cells are composed of infiltrating masses or nests of moderately differentiated cells, with
differentiation increasing from the periphery towards the center of the masses. The tumor
histology resembles that of invasive urothelial cell carcinoma along with regions of
squamous differentiation. Tumors derived from the cadmium transformants are similar to
the arsenic heterotransplants, but with less squamous differentiation (Sens et al., 2004).
Global analysis of changes in gene expression in the transformed isolates allows for
the investigation of metal-specific carcinogenic mechanisms and biomarkers for bladder
cancer staging, and prediction of progression and recurrence. Multiple independentlytransformed isolates were subjected to microarray analysis; that is, additional isolates
were derived from the parent UROtsa cell line with identical exposures (Garrett, Somji,
Sens, & Zhang, 2014). Multiple independently-transformed isolates allow for assessment
of variability and determination of commonly altered pathways, eliminating non-specific
gene expression. Tumor heterogeneity is an important issue in cancer research, both
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within individual tumors and within a single tumor (M Gerlinger & Swanton, 2010;
Marco Gerlinger et al., 2014; Sjöblom, 2008). Furthermore, UROtsa cells metabolize
inorganic arsenic to MMA(III) (Bredfeldt et al., 2004) and the different metabolites of
arsenic may give rise to a variety of changes. By comparing and contrasting changes in
gene expression in arsenic- and cadmium-transformed cells, the carcinogenesis pathways
unique to each metal may be elucidated, as well as common mechanisms of bladder
cancer progression.
Subcutaneous tumors derived from arsenic-transformed UROtsa cells display a
squamous phenotype, including expression of keratin 6 and 16 which are indicative of
early features of squamous differentiation (Cao et al., 2010). Subcutaneous tumors
derived from cadmium-transformed UROtsa cells display mild to prominent squamous
differentiation, as well (Somji et al., 2010). Keratin-6a, a gene involved in urothelial
proliferation and wound repair, is upregulated in cadmium-transformed UROtsa cells in
vitro and in mouse heterotransplant tumors. In the normal UROtsa cell line, keratin-6a
expression iss induced by insulin and EGF, suggesting that keratin-6a may be a marker
for cancer cells with an activated growth factor pathway (Somji et al., 2008). Keratin 6,
16, and 17 are correlated with areas of squamous differentiation in Cd heterotransplants.
Subcutaneous tumors derived from arsenic-transformed UROtsa cells demonstrate
intense focal staining for keratin 7 and 19. In general, cadmium and arsenic
transformation of UROtsa cells display similar patterns of keratin 6, 7, 16, 17 and 19 in
vitro and in tumors (Somji et al., 2011). Other studies have found that keratin 5/6
expression may distinguish reactive urothelial atypia from urothelial carcinoma in situ
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and the non-invasive compartment of high-grade papillary urothelial carcinoma
(Edgecombe, Nguyen, Djordjevic, Belanger, & Mai, 2012).
While metallothionein does not appear to play a large role in cancer initiation, its
induction due to heavy metals may be valuable as a biomarker of cancer progression.
Patterns of Metallothionein 1/2 in arsenic- and cadmium-transformed UROtsa
heterotransplants are similar to that of human high-grade bladder cancers, which is focal
in its expression (X. D. Zhou, Sens, Sens, et al., 2006). Metallothionein-3, which is
expressed in 96% of high-grade urothelial cancers, is observed in tumor heterotransplants
derived from arsenic- and cadmium-transformed UROtsa cells, as well (X. D. Zhou,
Sens, Garrett, et al., 2006), indicating that the metallothionein proteins may be useful as a
biomarker of high-grade bladder cancer.
SPARC, a protein involved in extracellular matrix synthesis and the promotion of
changes in cell shape, is decreased in arsenic- and cadmium-transformed UROtsa cell
lines and subcutaneous tumor heterotransplants. While the epithelial component of cells
is negative for SPARC, positive staining is observed in stromal cells. Negative epithelial
with positive stromal expression of SPARC is confirmed in human bladder cancer
specimens, as well (Jennifer Larson et al., 2010). In SPARC-null mice, development of
urothelial preneoplasia, neoplasia, and metastasis is increased, along with a reduction in
survival. SPARC also regulates chemical carcinogen-associated inflammation, ROS, and
cell proliferation (Said, Frierson, Sanchez-Carbayo, Brekken, & Theodorescu, 2013).
Neuron-specific enolase is induced in arsenic- and cadmium-exposed UROtsa cells,
as well as the transformed cell lines and tumor heterotransplants, suggesting a role in
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carcinogenesis. Protein expression was localized to the nucleus, suggesting alternatives to
its commonly known role in glycolysis (Soh et al., 2012).
Microarray analysis of the arsenic-transformed isolates reveal 328 genes commonly
induced and 91 repressed that had at least two-fold change for each isolate compared with
the control. In the cadmium-transformed isolates, 285 genes are commonly induced, with
215 repressed. (Garrett et al., 2014). The microarray consisted of six arsenic-transformed
and seven cadmium-transformed biological replicates. To assess statistical significance of
the numbers of commonly induced and repressed genes, a simulation study was designed
using randomly generated subsets of genes. The number of significantly induced or
repressed genes in common to all isolates was counted, and a new subset of genes was
then randomly selected. This simulation was performed 1,000,000 times, and the number
of differentially expressed genes never surpassed that found by the microarray (Garrett et
al., 2014).
Validation by PCR array was then performed. Genes which demonstrated less than
5% false discovery rate and greater than 3.2-fold change on the microarray were selected
for validation. In the microarray, each biological replicate was tested in triplicate. Results
from the PCR array were similar to those from the microarray, in which the percent of
genes which failed to validate was similar to the 5% false discovery rate utilized in the
microarray (Garrett et al., 2014).
To determine whether the number of isolates used for microarray were sufficient to
identify common gene sets, a model was developed to predict the number of commonly
induced or repressed genes as the number of isolates increased. With the addition of each
isolate, the number of common genes decreased. However, when the number of isolates
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reached four or five (depending upon the sample set), the number of common genes
stabilized, indicating that at this point the list of induced and repressed genes are truly
responsive to the cadmium or arsenite treatment. As the cadmium- and arsenictransformed UROtsa cells contained seven and six isolates, respectively, it was
determined that the commonly induced or repressed genes identified were responsive and
specific (Garrett et al., 2014).
Of the differentially induced genes confirmed by PCR in the arsenic-transformed
isolates, N-cadherin was the top-most consistently induced gene. In cadmiumtransformants, N-cadherin is the 5th most consistently induced gene (Figure 1.2) (Garrett
et al., 2014).

Figure 1.2 N-cadherin is consistently induced in As3+- and Cd2+-transformed
UROtsa cells. PCR array validation of microarray results indicates N-cadherin is
significantly induced in the majority of As3+-and Cd2+-transformed UROtsa isolates. PCR
results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01,
***p<0.001
N-cadherin
Cadherins are proteins that contribute to adherens junctions, named for their calciumdependent adhesive properties (Jäger et al., 2010). These Type 1 transmembrane proteins
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mediate homophilic cell adhesion and include epithelial-cadherin (E-cadherin), neuronalcadherin (N-cadherin), placental-cadherin (P-cadherin), and retinal cadherin (van Roy,
2014).
N-cadherin is normally expressed in the brain, vascular endothelial cells, and cardiac
and skeletal muscle cells. N-cadherin promotes the development of neuroepithelial
adherens junctions, axon migration, and synapse formation (Takeichi, 2007). Expression
of N-cadherin is a hallmark of the epithelial-to-mesenchymal transition (EMT), a process
which occurs in numerous cancers and is believed to promote invasion and metastasis
(Wheelock, Shintani, Maeda, Fukumoto, & Johnson, 2008).
During EMT, E-cadherin expression is often lost or decreased, leading to
destabilization of adherens junctions and loss of apical-basal polarity (C. Huang, Ke,
Costa, & Shi, 2004). E-cadherin is the main cadherin that promotes cell-cell adhesion and
polarity in epithelial tissues, supporting their differentiated state (Capaldo & Macara,
2007; Gumbiner, Stevenson, & Grimaldi, 1988). E-cadherin also sequesters β-catenin,
preventing activation of the Wnt signaling pathway and expression of oncogenes such as
cyclin D1 (Bryan & Tselepis, 2010). As such, the loss of E-cadherin expression in
bladder cancer is associated with increased stage, grade, and incidence of recurrence and
with decreased survival rate (Baumgart et al., 2007; B. Liu, Miyake, Nishikawa, &
Fujisawa, 2015; Muramaki et al., 2012; Muramaki, Miyake, Terakawa, Kusuda, &
Fujisawa, 2011; K M Rieger-Christ et al., 2001; Shimazui et al., 1996; Zhao, Dong, Sun,
Zhang, & Sun, 2014).
Additional changes include loss of other adhesion complexes and alterations in
morphology due to cytoskeletal restructuring (Lamouille, Xu, & Derynck, 2014). Cell
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motility is increased, facilitated by an enhanced ability to degrade extracellular matrix
proteins. Resistance to senescence and apoptosis is also elevated (Thiery, Acloque,
Huang, & Nieto, 2009).
N-cadherin expression during EMT promotes cell affinity for the extracellular matrix
and endothelial compartment, promoting cell survival and transendothelial migration
(Groen et al., 2011; Qi, Chen, Wang, & Siu, 2005). N-cadherin also interacts with and
stabilizes fibroblast growth receptors at the cell surface, enhancing its activity and
altering the downstream MAPK/ERK pathway leading to increased invasion (Suyama,
Shapiro, Guttman, & Hazan, 2002).
N-cadherin expression has been positively correlated with bladder cancer progression
and recurrence. In a study of 161 bladder cancer patients, N-cadherin expression levels
are correlated with tumor recurrence following removal of non-muscle-invasive
urothelial carcinoma of the bladder (B. Liu et al., 2015). In another study of 115 patients
with non-muscle-invasive bladder cancer following tumor removal, positive N-cadherin
expression is significantly associated with bladder cancer recurrence and significant
reduction in recurrence-free survival. Incidence of recurrence is significantly increased in
E-cadherin-negative and N-cadherin-positive tumors, and recurrence-free survival is
reduced (Muramaki et al., 2012). Recurrence-free survival is associated with negative Ncadherin expression in a study of urothelial carcinoma of the upper urinary tract after
removal of parts of the bladder and kidney (Muramaki et al., 2011). Lascombe et al.
examined N-cadherin expression in 101 tumors and found that mRNA expression is
increased in muscle-invasive versus superficial tumors, but comparable protein levels are
not detected (Lascombe et al., 2006). A study of 181 bladder cancer patients stratified by
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tumor invasiveness found that N-cadherin expression negatively correlates to survival in
all cases, but positively associates with survival in invasive cases (Jäger et al., 2010), and
no correlation is found between N-cadherin and stage, grade, lymph node involvement or
vascular invasion in a study of 572 bladder cancer patients (Baumgart et al., 2007).
Numerous transcription factors regulate the epithelial-to-mesenchymal transition,
including Twist, Snail, Slug, Zeb1, and Zeb2 (Lamouille et al., 2014). Differential
expression of Twist, a repressor of E-cadherin, has been noted in bladder cancer, in
which elevated Twist expression is correlated with bladder cancer stage, grade, and
poorer progression-free survival (Fondrevelle et al., 2009). The roles of other EMT
transcription factors in bladder cancer have not been fully elucidated. In a recent
immunohistochemical study of transcription factors in 49 samples of urothelial
carcinoma, Snail is correlated with local invasiveness, while Slug is associated with both
local and muscle invasion capacity, as well as metastasis. Zeb1 is significantly related to
invasiveness, but not metastasis (Schulte et al., 2012).
MicroRNAs also regulate EMT, particularly the miR-200 family which promotes the
epithelial phenotype and has been explored in bladder cancer. miR-200c is downregulated in bladder cancer specimens in a study by Liu et al., and its overexpression
results in decreased cell invasion, migration, and proliferation capabilities (L. Liu et al.,
2014). In another study, miR-200 family mRNAs are expressed in bladder cancers
displaying an epithelial phenotype, and the transcription factors Zeb1 and 2 are inversely
correlated with miR-200c expression. Further, miR-200c reverts EMT, inducing the
mesenchymal bladder cancer cell line UMUC3 to undergo epithelial differentiation,
further validating the role of miR-200c as a negative regulator of EMT (Adam et al.,
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2009). Loss of miR-141 and miR-200b is associated with increased invasion and
migration, Vimentin and N-cadherin expression, downregulated E-cadherin, and
increased metalloproteases in a study performed with the UM-UC-3 and HTB 9 bladder
cancer cell lines (W. Liu et al., 2015).
The EMT status of some human bladder cancer cell lines has been characterized,
though a common pattern of EMT progression has not been clarified. The cell lines RT4
and RT112 demonstrate an epithelial phenotype and morphology, with low to no
expression of the mesenchymal markers N-cadherin and Vimentin (Matsui et al., 2012).
The bladder cancer cell lines 5367 and 253J BV display both epithelial and mesenchymal
characteristics, with co-expression of N-cadherin and E-cadherin. Cell line 5367
demonstrates high levels of the pro-EMT transcription factor Slug but low expression of
Vimentin, while 253J BV has low Slug expression accompanied with high Snail levels,
another pro-EMT transcription factor, and is positive for Vimentin (Hänze, Henrici,
Hegele, Hofmann, & Olbert, 2013; Matsui et al., 2012; Wu et al., 2012). TCCSUP lacks
E-cadherin, with a moderate increase in N-cadherin expression. Vimentin is low in this
cell line, though it demonstrates mesenchymal morphology (Baumgart et al., 2007; Hänze
et al., 2013; Matsui et al., 2012). Cell lines J82 and T24 are the most mesenchymal,
showing a loss of E-cadherin accompanied by increased N-cadherin, as well as Vimentin
expression (Wu et al., 2012). Both cell lines demonstrate increased cell invasion capacity,
with T24 the highest (Wallerand et al., 2010).
Very little is known about the regulation of N-cadherin. A few transcription factors
have been investigated in the regulation of N-cadherin, though not in the context of
urothelial tissue expression. The transcription factor Twist, a basic helix-loop-helix
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protein and well-known repressor of E-cadherin expression, may also activate
transcription of N-cadherin. In a study by Alexander et al. in prostate cancer cells, Twist
depletion results in a decrease in N-cadherin expression. Using a luciferase assay, coexpression of Twist and the 5’ promoter construct for N-cadherin shows no increase in
promoter activity. However, co-expression of Twist with an E-box sequence within the
first intron of N-cadherin results in significant increases in promoter activity. Further
analysis by electrophoretic mobility shift assay reveals Twist binding at +2,627, within
the first intron of N-cadherin (Alexander et al., 2006). This regulation displays similarity
with that of E-cadherin, which is regulated at the first and second introns in vivo
(Stemmler, Hecht, Kinzel, & Kemler, 2003). Further evidence of dual regulatory function
is seen in the activation of YB-1 and AKT-2 by Twist (Cheng, Zhang, & Wang, 2008;
Shiota et al., 2008). The mechanisms that underlie its dual transcriptional mode are not
fully elucidated, though recruitment of epigenetic factors have been implicated (F. Yang
et al., 2012).
Activating protein 1 (AP-1), a heterodimer formed of c-Jun and c-Fos, is another
potential transcription factor regulating N-cadherin expression. AP-1 regulates
transcription of N-cadherin in Schwannoma cells (Martiáñez, Lamarca, Casals, & Gella,
2013). Further, AP-1 activity may be altered in urothelial cells by arsenic exposure.
Exposure to four weeks of sodium arsenite in mice induces hyperplasia of the bladder
urothelium and an increase in DNA binding of AP-1. In transgenic mice containing an
AP-1 luciferase reporter, arsenite exposure promotes AP-1 transactivation. In vitro
experiments using a human bladder epithelial cell line also demonstrate increased AP-1
DNA binding following arsenite treatment (Simeonova et al., 2000, 2001). In addition,
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exposure to methylarsine oxide or iododimethylarsine promotes phosphorylation of c-Jun
and AP-1 DNA binding, and was found to be more potent than arsenite in promoting AP1 activity (Drobná, Jaspers, Thomas, & Stýblo, 2003).
NFĸB may also regulate N-cadherin transcription. Electrophoretic mobility shift
assays for NFĸB DNA binding reveal strong binding activity at the N-cadherin promoter
in melanoma cells. Reporter gene assays showed that NFĸB binding activates N-cadherin
transcription (Kuphal & Bosserhoff, 2006). In UROtsa cells, MMA(III) exposure induces
the translocation of NFĸB to the nucleus, suggesting that arsenic may induce N-cadherin
expression through NFĸB to promote bladder cancer progression (Escudero-Lourdes,
Medeiros, Cárdenas-González, Wnek, & Gandolfi, 2010).
The transcription factors specificity protein 1 (SP1) and 2 (SP2) show evidence of
regulatory function, as well. Electrophoretic mobility shift assays in human osteoblasts
indicate that an Sp1/Sp3 binding site regulates N-cadherin expression. Specifically, Sp3
antagonizes Sp1-induced transcription (Le Mée, Fromigué, & Marie, 2005). In a series of
experiments studying the anti-proliferative, anti-angiogenic, and pro-apoptotic activity of
arsenic trioxide in bladder cancer cells, arsenite-responsive cell lines displayed oxidative
stress-dependent decreases in Sp1, Sp3, and Sp4 expression. A number of additional
studies in other cell types have also found downregulation of Sp1 following arsenic
exposure (Ai et al., 2007; Chou et al., 2005; Y. Zhang et al., 2015). Cadmium is also
associated with reduced Sp1 activity (Aiba, Hossain, & Kuo, 2008; Kothinti, Blodgett,
Tabatabai, & Petering, 2010; Y. Li, Kimura, Huyck, Laity, & Andrews, 2008; Watkin,
Nawrot, Potts, & Hart, 2003; Youn et al., 2005), suggesting that Sp1 and/or Sp3 may
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mediate arsenic- and cadmium-induced alterations in N-cadherin expression in the
progression of bladder cancer.
Other transcription factors shown to have regulatory activity at the N-cadherin
promoter include RBPJ (Fangfei Li et al., 2011), GATA-4 (H. Zhang, Toyofuku, Kamei,
& Hori, 2003), SOX-9 (Panda, Miao, Lefebvre, Hendy, & Goltzman, 2001), MZF1 (Le
Mée et al., 2005), and SMAD4 (Kang et al., 2014). However, these transcription factors
have not been associated with bladder cancer progression or arsenic and cadmium
exposure.
Bladder Cancer Characteristics and Research Needs
In 2011, it was estimated that 571,518 individuals were living with bladder cancer in
the United States (Howlader et al., 2014). 74,690 new cases of bladder cancer were
estimated for 2014 in the United States, with 15,580 deaths due to the disease (Malats &
Real, 2015). Bladder cancer is the 9th leading cause of death in the United States. The
median age at diagnosis is 73, with bladder cancer more common in men than women
(Howlader et al., 2014). The annual cost of bladder cancer was $4 billion in the United
States. when estimated in 2010, and it is predicted to rise to $5 billion by 2020 (Yeung,
Dinh, & Lee, 2014).
The bladder is composed of a mucosa lined by transitional epithelium, muscularis,
and adventitia. The number of layers of the transitional epithelium can vary from six
when the bladder is empty, to three when the bladder is distended. (Ross & Pawlina,
2011). The urothelium consists of a basal layer, intermediate layer, and superficial layer,
with cells increasing in differentiation from base to surface. Extensive interdigitations of
cytoplasmic processes and desmosomes create lateral connections throughout, while
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superficial cells are linked by tight junctions to create an impermeable barrier (Jost,
Gosling, & Dixon, 1989). The superficial, or umbrella cells, are usually cuboidal and
bulge into the lumen. Further, in the distended bladder, umbrella cells flatten and unfold
to increase available surface area. The normal urothelium has a very low proliferative
capacity, wherein basal cells act as progenitors. Upon pathological damage, both basal
and intermediate cells will rapidly regenerate the urothelium (Ho, Kurtova, & Chan,
2012). Underlying the transitional epithelium is the lamina propria, a dense collagenous
layer, followed by the muscularis. The muscularis contains longitudinal and circular
layers of smooth muscle which aid the movement of urine through the ureter to the
bladder (Ross & Pawlina, 2011).
The majority of bladder cancers are transitional cell carcinoma, with less than ten
percent composed of squamous cell carcinoma and adenocarcinoma. Small cell
carcinoma and sarcoma of the bladder are rare (Cubilla et al., 2004). Transitional cell
carcinoma is widely categorized by the extent of its invasion into surrounding tissue.
There are two types of non-muscle-invasive transitional cell neoplasms: flat and papillary
lesions. Of the flat lesions, carcinoma in situ is a known precursor of invasive cancer.
This lesion contains cells with irregular, large, hyperchromatic nuclei (See Figure). Most
patients have multifocal or diffuse carcinoma in situ cells (Figure 1.2.A). Papillary
lesions often occur in multiples, and frequently recur following local resection (Figure
1.2.B). Patients with a history of papillary tumors are at risk for developing invasive
carcinoma (Al-ahmadie, Lin, & Reuter, 2011). The grading of papillary neoplasms is
widely debated, but the current system is based on architectural and cytologic changes in
the urothelium. With increasing grade, papillary carcinoma progression rates are
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elevated. Invasive urothelial carcinoma includes tumors which invade the muscularis
mucosae or the muscularis propria (Figure 1.3). These tumors have variable histology,
though depth of invasion is important for staging (Cubilla et al., 2004).

Figure 1.3 In situ and papillary urothelial carcinoma. A) Urothelial carcinoma in situ
and B) Papillary urothelial neoplasm of low malignant potential. Adapted from (Alahmadie et al., 2011).
Squamous cell carcinoma is characterized by keratin pearls, intercellular bridges, and
keratotic cellular debris. At the time of diagnosis, most squamous cell carcinomas are
poorly differentiated and deeply invasive, possibly contributing to the poor prognosis of
these tumors (Al-ahmadie et al., 2011).
Seventy percent of bladder cancers are confined to the bladder and are non-muscleinvasive. While only 5-10% of those will progress and infiltrate the bladder, half of noninvasive bladder cancers will recur (Simon et al., 2004).
Cancer grade is a prediction of cancer progression, while stage characterizes tumor
size and spread. The American Joint Committee on Cancer designated 6 stages of bladder
cancer (0a, 0is, I, II, III, and IV) determined by tumor type (papillary or in situ and extent
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of bladder invasion), presence of lymph node metastasis, and indication of distant
metastasis (Rubin & Hansen, 2012).

Figure 1.4 Varying levels of invasive urothelial carcinoma. A) Invasion into lamina
propria. B) Invasion into deep lamina propria. B) Invasion into muscularis propria.
Adapted from (Al-ahmadie et al., 2011).
The most common symptom of bladder cancer is painless hematuria. Cystoscopy
is the gold standard for evaluation of bladder cancer, in which tumor location, size, and
appearance is determined (Kamat et al., 2013). Transurothelial resection or biopsy is then
performed for histological examination of cancer type and stage. Cytology is also used
for detection of high grade cancer and to monitor patients for recurrence following
treatment. In cytology, cells found in urine are analyzed for abnormalities indicating
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neoplasia. The clinical value of cytology for the management of urothelial cancer is
variable, as it only has strong sensitivity in high-grade bladder cancers (Al-ahmadie et al.,
2011).
Bladder cancer has the highest lifetime cost per person (Yeung et al., 2014), with
60% of costs due to surveillance and treatment of recurrence (Avritscher et al., 2006).
Surveillance has been identified as a target for improvement in economical efficacy
(Svatek et al., 2014). Tumor biomarkers may be a promising route to determining bladder
cancer recurrence. Tumor biomarkers do not add additional invasive procedures, as
analysis utilizes previously resected tumors. Upon initial tumor resection, evaluation of
biomarkers could provide information about potential recurrence, reducing the number of
cystoscopies and allowing for earlier detection of tumor recurrence (Lotan et al., 2010). A
number of tissue-based biomarkers have been developed, though none are yet ready for
use in clinical settings (Kamat et al., 2013).
Hypothesis and Rationale
This body of work tests the hypothesis that As3+ and Cd2+ induce bladder cancer
through EMT mechanisms. In the first study, the role of N-cadherin, a pro-EMT marker,
in bladder cancer caused by As3+ and Cd2+ will be determined both in vitro and in animal
models. The finding that N-cadherin was the top-most consistently induced gene in
arsenic transformed UROtsa cells and a top induced gene in cadmium transformed
isolates suggests that the gene may play an instrumental role in the process of malignant
transformation, and that it could be developed as a biomarker of heavy metal-induced
bladder cancer. The fact that N-cadherin expression is maintained in transformants
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following removal of arsenic and cadmium also implies a mechanism of permanent gene
activation, and the role of epigenetic regulation will be explored.
To further establish the role of EMT in As3+- and Cd2+- induced bladder cancer,
additional markers of the transition will be characterized. While EMT is considered the
mechanism by which cancers progress and become metastatic, the details of the process
are unique to cell type and inducing agent, and have not been elucidated in bladder
cancer.
The As3+- and Cd2+ transformed UROtsa cell lines are a valuable tool for
distinguishing the characteristics of bladder cancer induced by heavy metals. Further, this
model system demonstrates metal-specific EMT mechanisms of bladder cancer
progression. With these tools at hand, sensitive and specific biomarkers may be
elucidated to better detect and predict bladder cancer progression.
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CHAPTER II
METHODS
Cell Culture
The human urothelial cell line UROtsa was immortalized and cultured as
described in Rossi et al. 2001. Briefly, cells were grown in 75 cm2 cell culture flasks with
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) supplemented with 5% v/v fetal
calf serum (Gibco). Cells were maintained at 37 oC in a 5% CO2/95% air atmosphere.
Upon reaching confluency, cells were subcultured at a 1:3 ratio with 0.25% trypsin/
EDTA (Gibco). Cells were fed every three days with growth medium.
UROtsa cells were transformed with arsenite and cadmium as previously
described (Sens et al., 2004). Briefly, UROtsa cells were cultured under identical
conditions and transformed with 1µM cadmium chloride and sodium (Sigma-Aldrich) in
the media. Cells were harvested periodically throughout the transformation. The resulting
seven Cd2+ and six As3+ isolates were expanded ten times at a 1:20 ratio before use. All
isolates were able to form colonies in soft agar as described in Sens et al. 2004. Cells
were maintained in DMEM supplemented with 5% fetal calf serum and 1% glucose and
subcultured at a 1:10 ratio.
Human bladder cancer cell lines J82, RT4, and TCCSUP were purchased from
ATCC and cultured in DMEM with 10% fetal calf serum,1% glucose, and 2.5%
nonessential amino acids.
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For short-term heavy metal exposure experiments, the parent UROtsa cell line
was passaged with DMEM containing 1 µM sodium arsenite or cadmium chloride for 30
days. Cells were harvested for PCR and Western blot analysis at each passage.
Microspheres were derived from cell monolayer cultures by seeding at low
density on low-adherance flasks. The parent UROtsa cells were grown in serum-free
DMEM, and transformed isolates were cultured in 20/12 media.
AZC and HDACi
Parent UROtsa cells were seeded 1:10 and treated the following day with 5-Aza-2’deoxycytidine (5-AZC) (Sigma-Aldrich) or MS-275 (ALEXIS Biochemicals). Cells were
exposed to 0.5, 1, 1.5 and 3 µM 5-AZC or 1, 3, and 5 µM MS-275 for three days. Upon
reaching confluency, cells were harvested for PCR analysis.
Heterotransplant Tumors
Heterotransplant tumors were formed by subcutaneous (SC) injection of the
transformed isolates in nude mice as described in Sens et al. 2004. In short, NCr-nu/nu
mice were inoculated with 1 x 106 cells in 0.2 ml phosphate-buffered saline. Mice were
sacrificed after 10 weeks or if conditions warranted euthanasia. Individual tumors were
split for RNA isolation, protein isolation, and immunohistochemistry.
To observe the ability of tumors to colonize internal organs of the peritoneum,
transformed cells were implanted into nude mice via intraperitoneal injection as
described in Cao et al. (2010). Briefly, 1 x 106 cells in phosphate-buffered saline (PBS)
were injected into the lower right quadrant of the abdominal cavity. Mice were
euthanized 53 days later when tumors became visible and large in some mice. Following
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necropsy, tumors and their associated organs were formalin fixed and paraffin embedded
for histology or flash frozen for molecular techniques.
Real Time RT-PCR
Total RNA was isolated using the TRI Reagent protocol (Molecular Research Center,
Inc.) and quantified by spectrophotometry (Nanodrop). Tumor samples were snap frozen
and ground to a powder with liquid nitrogen before RNA isolation.
One hundred ng of purified RNA was subjected to cDNA synthesis using the iScript
cDNA synthesis kit (Bio-Rad) in a total volume of 20 µl. Real time PCR was performed
with SYBR Green (Bio-Rad) using 10 ng of cDNA. Amplification was performed using
the iCycler MyiQ real time detection system (Bio-Rad) and measured by SYBR Green
fluorescence. Primers used are indicated in Table 2.1.
Gene
ALDH1A1
CD44
CDH1
CDH2
eEF1A2
EPHA4
ETV7
IL1RN
LIMCH1
LPHN2
NR2F1
NR2F2
NTF3
OCLN
Slug
Snai1
STEAP1
TCF4
Twist
UGT8
Vimentin
Zeb1
Zeb2

Company
Qiagen
Qiagen
BioRad
Qiagen
BioRad
BioRad
BioRad
BioRad
BioRad
BioRad
BioRad
BioRad
BioRad
BioRad
Qiagen
Qiagen
BioRad
Qiagen
Qiagen
BioRad
BioRad
Qiagen
Qiagen

Table 2.1 Primer source information
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Catalog No.
QT00013286
QT00073549
qHsaCED0042076
QT00063196
qHsaCID0011054
qHsaCID0017961
qHsaCED0037660
qHsaCID0014491
qHsaCID0010779
qHsaCID0010674
qHsaCED0047128
qHsaCID0015621
qHsaCED0004155
qHsaCED0038290
QT00044128
QT00010010
qHsaCED0046236
QT00031829
QT00011956
qHsaCID0017816
qHsaCID0012604
QT01888446
QT01867586

Levels of gene expression were determined using quantitative and relative standard
curves. Samples were normalized to β-actin (forward, 5CGACAACGGCTCCGGCATGT-3 and reverse, 5-TGCCGTGCTCGATGGGGTACT3). The resulting levels were then expressed as fold change over the parent UROtsa cell
line.
Analysis of PCR results was performed by one-way analysis of variance (ANOVA)
and Tukey or Dunnett’s post-test. Data was represented as mean SEM of triplicate
determinations with *p<0.05, **p<0.01, and ***p<0.001. GraphPad Prism 5 was used for
all analyses.
Western Blot Analysis
Total protein was isolated from cell pellets and tumor tissue using 2% SDS 50 mM
Tris-HCl, pH 6.8 with 1% protease inhibitor cocktail (Sigma-Aldrich). Tissue was frozen
and ground to powder with liquid nitrogen before homogenizing in lysis buffer. Samples
were boiled for 10 min followed by DNA shearing by sonication. Protein concentration
was determined by BCA assay (Pierce). Samples were stored at -80 oC in 100 mM
dithiothreitol.
Fifteen µg protein was separated by SDS-PAGE using the TGX AnyKd SDS
polyacrylamide gel (BioRad). Samples were reduced in β-mercaptoethanol and boiled for
5 min prior to loading. Protein was transferred to a 0.2 µm PVDF membrane using the
semi-dry technique followed by blocking in 5% nonfat dry milk in TBS-T for 90 min.
Blots were incubated overnight at 4 oC in the primary antibodies N-cadherin (Invitrogen,
cat# 333900, 1:1,000), E-cadherin (Santa Cruz, sc-7870, 1:1,000), β-actin (AbCam,
ab8226, 1:1,000), eEF1A2 (Abnova, H00001917-A01, 1:1,000) and NT-3 (Santa Cruz,
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sc-547, 1:200). Blots were probed with appropriate HRP-conjugated secondary
antibodies (Cell Signaling) and visualized using Clarity Western ECL (BioRad).
Immunofluorescence
Parent UROtsa and transformed cells were cultured in 24-well plates containing
12 mm coverslips. Confluent cultures were fixed in ice-cold 100% methanol for 3-5 min
at -20 oC. Cells were then incubated in rabbit α-human E-cadherin primary antibody
(Santa Cruz, sc-7870) at 2 µg/ml followed by incubation with 2 µg/ml of goat α-rabbit
Alexa Fluor 594-tagged secondary antibody (Invitrogen, A11012). Cells were then
incubated with mouse α-human N-cadherin primary antibody at 10 µg/ml followed by 2
µg/ml goat α-mouse secondary antibody Alexa Fluor 488 (Invitrogen, A11001). All
antibody incubations were done at 37 oC for 45 min each. Images were captured with a
Leica DM5500 Q TCS SPE confocal system and Z-slices were imaged at the indicated
optimal depth, stacked and processed using LAS-AF software and Adobe Photoshop.
Immunohistochemistry
Serial sections of subcutaneous and intraperitoneal tumors were cut at 3-5 µm for
use in immunohistochemical protocols. The primary antibodies used were: polyclonal
rabbit α-E-cadherin (Santa Cruz, 1:100), monoclonal mouse α-N-cadherin (Invitrogen,
1:100) and polyclonal rabbit α-Snail (Cell Signaling, 1:100). Immunohistochemical
staining was performed on Leica Bond-Max Automated IHC Staining System (Leica,
Bannockburn, IL). Paraffin sections were processed in the machine from
deparaffinization until counterstaining by hematoxylin according to the manufacturer’s
recommended program with modification. Bond Polymer Refine Detection (Leica,
DS9800) was used as the main reagents in the automatic staining process. Briefly, the
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major steps includes deparaffinization, antigen retrieval in Bond Epitope Retrieval
Solution 1 (Leica, Catalog No AR9961) for 20 min, peroxide block for 5 min, incubation
with primary antibodies for 25 min at room temperature, incubation with Post Primary for
10 min, incubation with Polymer for 10 min, visualization with DAB for 10 min, and
counterstaining with hematoxylin for 5 min. Slides were rinsed in distilled water,
dehydrated in graded ethanol, cleared in xylene, and coverslipped. The presence and
degree of immunoreactivity in the specimens was judged by two pathologists. The scale
used was 0 to +3 with 0 indicating no staining, +1 staining of mild intensity, +2 staining
of moderate intensity, and +3 staining of strong intensity.
Chromatin Immunoprecipitation
The ChIP-ITTM Express kit from Active Motif was used for chromatin
immunoprecipitation experiments. UROtsa parent cells were passaged five times in 1 µM
cadmium chloride or sodium arsenite, followed by 48 hr exposure to MS-275 or 5-AZC.
Cells were grown to confluency in 75 cm2 flasks and fixed with 1% formaldehyde for 10
min. Cross linking was stopped with 0.125 M glycine stop solution and cells were
scraped with 2 ml PBS containing Phenylmethylsulfonyl fluoride (PMSF). Cells were
pelleted and resuspended in ice-cold lysis buffer, and homogenized using an ice-cold
dounce homogenizer. Nuclei were pelleted and resuspended in digestion buffer
containing PMSF and protease cocktail inhibitor. Chromatin was then sheared using
enzymatic shearing cocktail at 37 oC for 5 min, resulting in chromatin fragments of 2001,500 bp. Protein G-coated magnetic beads were incubated with 7 µg sheared chromatin
and 3 µg antibody overnight at 4 oC. Antibodies for trimethylated Histone 3 Lysine 9
(Active Motif), trimethylated H3K27 (Active Motif), and anti-acetyl Histone 4
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(Millipore). Samples were washed and the immune complex was then eluted.
Crosslinking was reversed using crosslinking buffer, and DNA was analyzed by
conventional PCR using the Gene Amp PCR core kit (Applied Biosystems). Primers
were designed for two regions of the N-cadherin promoter. Region 1 targeted a 72 bp
sequence using forward primer, 5- CGGCCCGCTATTTGTCATCAGCTC-3 and reverse,
5-CTCCCCACCCCCTTCTTCGC-3. An annealing temperature of 6 2oC was used for
Region 1. Region 2 targeted a 84 bp sequence using forward primer
5-ACGAGCCCGAAACCTCGCGTG-3 and reverse primer
5- ACCTTGGCCGGTGGAGGATGTGGA-3 with an annealing temperature of 61 oC.
PCR products were run on gel electrophoresis and band optical density was quantified
using Image Lab software (BioRad). Results were normalized to the amount of
corresponding DNA sequence from the fragmented chromatin solution prior to
precipitation.
Flow Cytometry
Cells were dissociated in 0.1% trypsin, 0.5mM CaCl2 in PBS followed by 0.5 ml
10 mM EDTA. Non-specific staining was blocked using 1% bovine serum albumin
(BSA) for 15 min on ice. Phycoerythrin (PE)-conjugated N-cadherin (mouse mAb clone
8C11, Biolegends cat # 350806) was added to cells at 1:10 and incubated at 4 oC in the
dark for 30 min. Samples were washed two times in 0.1% BSA in PBS buffer before flow
cytometry analysis. Cells were counted with a BD LSRII using FACSDiva software.
Results were gated to exclude doublets and identify the singlet population
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CHAPTER III
RESULTS
N-cadherin Induction in As3+- and Cd2+-transformed UROtsa Cells
To confirm the induction of N-cadherin observed by microarray, real time RTPCR was performed in the As3+ and Cd2+ isolates. Expression was found to be
significantly elevated compared to the non-malignant parent UROtsa cell line in the
majority of isolates. N-cadherin was induced an average of 20-fold in As3+ transformants,
and 5 to10-fold in Cd2+ isolates (Figure 3.1.A, B). Western blot analysis showed protein
levels comparable to that of mRNA (Figure 3.1.C, D).

Figure 3.1 N-cadherin expression is elevated in As3+- and Cd2+-transformed UROtsa
cells. Real time RT-PCR analysis of N-cadherin in parent UROtsa cell line and A) As3+
isolates, and B) Cd2+ isolates expressed as fold change normalized to β-actin. Western
blot analysis of N-cadherin protein in A) As3+ isolates, and D) Cd2+ isolates. PCR results
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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Immunofluorescence experiments were performed using a subset of the As3+- and
Cd2+-transformed isolates. Results showed that N-cadherin was localized to the plasma
membrane (Figure 3.2), with the most staining observed in isolate As#6 (Figure 3.2.D).
N-cadherin staining was only observed at regions of cell-cell contact (Figure 3.3). The
parent UROtsa cell line showed positive staining in a very small percentage of cells
(Figure 3.2.A), while no N-cadherin staining was observed in Cd2+ #7 (data not shown).

Figure 3.2 N-cadherin is highly expressed in As3+ isolate #6. N-cadherin expression is
localized to the plasma membrane. Immunofluorescence staining for N-cadherin in A)
parent UROtsa cells, B) Cd#1, C) As#3, and D) As#6. Cd#4 was also stained for Ncadherin, but showed no positive labeling. Bar= 25 µM.
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Figure 3.3 N-cadherin is expressed at cell-cell junctions. In N-cadherin-positive cells,
the protein is localized to regions of cell-cell contact. Image A represents highly
confluent As#6 cells with N-cadherin expression on all sides of the cell. Image B displays
a region of less confluent As#6 cultures in which N-cadherin localization is evident only
at regions of cell-cell contact.
Expression of N-cadherin was then measured in tumors formed by subcutaneous
(SC) injection of transformed isolates into nude mice. Surprisingly, N-cadherin was not
maintained in the subcutaneous heterotransplants at the mRNA or protein level (Figure
3.4). Immunohistochemical staining was also negative for N-cadherin in both As3+- and
Cd2+-transformed tumors (Figure 3.5, 3.6). The tumor cells were negative for NCadherin, but the stromal cells showed focal weak staining of N-Cadherin. The staining
of N-Cadherin in As#2 was a little stronger than other groups (Figure 3.5.B), while As#5
was almost negative (Figure 3.5.E). Some strongly positive structures are non-specific
signal. N-cadherin was then investigated in tumors derived from intraperitoneal (IP)
heterotransplants, in which positive focal staining was seen (Figure 3.7).
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Figure 3.4 N-cadherin mRNA and protein levels are unchanged in subcutaneous
heterotransplant tumors derived from As3+- and Cd2+-transformed isolates. A) Real
time RT-PCR analysis of N-cadherin in A) parent UROtsa cell line and As3+ isolates, and
B) parent UROtsa cell line and Cd2+ isolates expressed as fold change normalized to βactin. C) Western blot analysis of N-cadherin protein in C) As3+ isolates, and D) Cd2+
isolates. PCR results represent Mean ±SEM of triplicate determinations. *p<0.05,
**p<0.01, ***p<0.001
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Figure 3.5 Immunohistochemical analysis demonstrates negative staining in
subcutaneous heterotransplant tumors derived from As3+-transformed isolates. The
tumor cells are negative for N-Cadherin, but the stromal cells show focal weak staining
of N-Cadherin. The staining of N-Cadherin in As #2 is a little stronger than other groups,
and As#5 is almost negative. Some strongly positive structures are non-specific signal. A)
As#1, B) As#2, C) As#3, D) As#4, E) As#5, F) As#6. Magnification 200X.
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Figure 3.6 Immunohistochemical analysis demonstrates negative staining in
subcutaneous heterotransplant tumors derived from Cd2+- transformed isolates. The
tumor cells in Cd2+ tumors are negative for N-Cadherin, but the stromal cells show focal
weak staining of N-Cadherin. Some strongly positive structures are non-specific signal.
A) Cd#1, B) Cd#2, C) Cd#3, D) Cd#4, E) Cd#5, F) Cd#6, G) Cd#7. Magnification 200X.
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Figure 3.7 N-cadherin is focally expressed in intraperitoneal tumors. In contrast to
subcutaneous tumors, the all 3 IP tumors show focal weak staining of N-Cadherin. The
strongly N-Cadherin positive round structures are non-specific staining. A) As#1, B)
As#3, C) Cd#1. Magnification 200X
Cell population heterogeneity may be a cause of the inconsistent results for Ncadherin expression in vivo. During transformation, numerous phases of massive die-off
followed by regrowth of surviving colonies occurred, allowing the opportunity for some
heterogeneity in the population to arise. To investigate whether the lack of a clonal
population played a part in tumor phenotype, flow cytometry was performed for Ncadherin among isolates with varying N-cadherin expression as observed by PCR and
Western blot. The As3+ isolates #1, #3, and #6 were chosen for their low, moderate, and
high expression of N-cadherin protein, respectively (Figure 3.1.C). The Cd2+-transformed
isolates #4, #1, and #5 similarly demonstrated low, medium, and high N-cadherin protein
relative to parent UROtsa cells in previous experiments (Figure 3.1.D). Flow cytometric
analysis using PE-conjugated N-cadherin antibody indicated a dramatic increase in the
percent of cells positive for N-cadherin in As3+ isolate #6 alone (Figure 3.8, Table 3.1),
with 98.5% of cells positive for N-cadherin in isolate #6 compared to 1.31% in the parent
UROtsa cell line. For the remaining isolates, less than 2% were positive for N-cadherin.
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Figure 3.8 The As3+ isolate #6 has dramatically increased numbers of N-cadherinpositive cells. Flow cytometry analysis for N-cadherin indicated by PE fluorescence in
parent and As3+ #6. Negative samples are no antibody controls.

Isolate
As #1
As #3
As #6
Cd #1
Cd #4
Cd #5
Parent

Cells
(Number)
7896
7317
7536
7140
8072
6868
4437

Low
Low
Moderate Moderate
High
High
N-cadherin N-cadherin N-cadherin N-cadherin N-cadherin N-cadherin
(Number) (Percent) (Number) (Percent) (Number) (Percent)
6257
3840
2
3325
5725
1866
1677

79.2
52.5
0.027
46.6
70.9
27.2
37.8

994
2982
9
3207
1736
4354
2583

12.6
40.8
0.12
44.9
21.5
63.4
58.2

65
117
7426
101
77
60
58

0.82
1.6
98.5
1.41
0.95
0.87
1.31

Table 3.1 As3+ isolate #6 has the highest percentage of N-cadherin-positive cells.
Table indicates number and percent of cells positive for low, medium, and high intensity
PE-conjugated N-cadherin. Negative samples indicate no antibody controls.

The fact that all isolates formed tumors lacking N-cadherin, independent of its
expression in vitro, suggested that a unique subset of cells negative for N-cadherin
existed within the cell population, and that this subset was responsible for tumor
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formation. The potential for tumor-initiating cells, or cancer stem cells, was then
investigated. Indeed, microspheres were derived from transformants by seeding at low
density on low-adherence flasks, a typical protocol for initial cancer stem cell isolation.
Further, the individual cells were able to regenerate microspheres following repeated
dissociation, confirming their self-renewal capability. Upon IP injection into nude mice,
the microspheres were also able to initiate tumor formation, further indicating their
cancer stem cell-like characteristics. PCR analysis for cancer stem cell markers was
performed, revealing that the microspheres expressed increased levels of ALDH1A1,
though CD44 expression was reduced relative to the corresponding isolates (Figure
3.9.A, B). Upon investigation of N-cadherin in the microspheres, mRNA levels were
compared to their corresponding transformed isolates, indicating that this putative cancer
stem cell population does not express N-cadherin (Figure 3.9.C).

Figure 3.9 Microspheres originating from As3+- and Cd2+-transformed isolates
express cancer stem cell marker ALDH1A1, but low levels of N-cadherin. A) Real
time RT-PCR analysis of A) ALDH1A1 in parent UROtsa cells, As3+ and Cd 2+
transformants and corresponding microspheres, B) CD44, and C) N-cadherin in parent
UROtsa cells, As3+ and Cd 2+ transformants and corresponding microspheres expressed as
fold change normalized to β-actin. PCR results represent Mean ±SEM of triplicate
determinations. *p<0.05, **p<0.01, ***p<0.001
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The transcriptional regulation of N-cadherin is largely unknown. While a number
of transcription factors have been implicated in various tissues, no studies are available
on the regulation of N-cadherin in bladder cancer progression through EMT. To
determine whether N-cadherin expression is a participant in cancer initiated specifically
by As3+ or Cd2+, rather than a change occurring downstream of carcinogenesis, nonmalignant parent UROtsa cells were exposed to 1 µM CdCl2 or NaAsO2. Sodium arsenite
failed to induce N-cadherin expression (Figure 3.10.A), while mRNA and protein levels
were induced beginning at 15 days of cadmium exposure (Figure 3.10.B, C).
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Figure 3.10 N-cadherin expression is induced in parent UROtsa cells exposed to
1 µM CdCl2 over 30 days. A) Real time RT-PCR analysis of N-cadherin over 30 days
exposure to 1 µM sodium arsenite expressed as fold change normalized to β-actin. B)
Real time RT-PCR analysis of N-cadherin over 30 days exposure to 1 µM cadmium
chloride expressed as fold change normalized to β-actin. C) Western blot analysis of Ncadherin protein over 30 days exposure to 1 µM cadmium chloride. PCR results represent
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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Interestingly, the expression of N-cadherin is maintained in As3+- and Cd2+transformed cells after removal of the heavy metals, indicating that permanent changes in
gene regulation have taken place. To determine whether epigenetic modifications may
play a role in N-cadherin expression, parent UROtsa cells were treated with the histone
deacetylase inhibitor MS-275 and the DNA methyltransferase inhibitor 5’-azacytidine (5AZC). Expression of N-cadherin mRNA was induced in a dose-dependent manner upon
MS-275 exposure (Figure 3.11.A), whereas very little change was seen after exposure to
5-AZC (Figure 3.11.B), indicating that histone acetylation state may regulate expression
of N-cadherin in UROtsa cells.

Figure 3.11 N-cadherin expression is altered by MS-275 exposure, while relatively
unchanged following 5’-AZC. A) Real time RT-PCR analysis of N-cadherin following
24 hr treatment with 0, 1, 3, and 10 µM MS-275. Expressed as fold change normalized to
β-actin. B) Real time RT-PCR analysis of N-cadherin following 48 hr treatment with 0,
0.5, 1, 1.5, and 3 µM 5’-AZC. Expressed as fold change normalized to β-actin. PCR
results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01,
***p<0.001
To further investigate the role of histone modification on N-cadherin
transcription, chromatin immunoprecipitation (ChIP) was performed for histone 4 total
acetylation and histone 3 lysine 9 trimethylation at two regions within 2,000 bp upstream
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of the N-cadherin transcription start site (Figure 3.12). Exposure to cadmium and arsenite
did not alter H3K9Me3 at Region 1. In addition, MS-275 treatment did not change
H3K9Me3 levels at this region (Figure 3.13). At Region 2, parent UROtsa cell exposure
to sodium arsenite for five passages led to increased H4Ac levels (Figure 3.14).
Cadmium chloride treatment induced H4Ac after 48 hrs, though the increased levels were
not maintained long-term. However, treatment with histone deacetylase MS-275
dramatically induced H4Ac in all treatment groups (Figure 3.14).

Figure 3.12 Schematic illustration of the N-cadherin promoter.

Figure 3.13 Histone 3 lysine 9 trimethylation is unchanged at Region 1 of the Ncadherin promoter following MS-275, As3+, or Cd2+ exposure. A) Ethidium bromidestained gel showing amplification of H3K9Me3 using semiquantitative PCR. B)
Quantified results of H3K9Me3 normalized to percentage of input.
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Figure 3.14 Arsenite exposure and MS-275 increase total histone 4 acetylation at
Region 2 of the N-cadherin promoter. A) Ethidium bromide-stained gel showing
amplification of H4Ac using semiquantitative PCR. B) Quantified results of H4Ac
normalized to percentage of input. P5 indicates exposure through five passages of cell
culture.
EMT Progression in As3+- and Cd2+-transformed UROtsa Cells
The levels of E-cadherin were determined both in vitro and in heterotransplants
originating from As3+ and Cd2+ isolates. E-cadherin was unchanged at the mRNA level in
both As3+- and Cd2+-transformed UROtsa cells (Figure 3.15.A), and no alterations were
seen in protein as determined by Western blot analysis (Figure 3.15.B).
Immunofluorescent staining for E-cadherin demonstrated localization of the protein at the
cell membrane at regions of cell to cell contact. E-cadherin was consistently labeled in all
isolates examined (Figure 3.16). Co-immunofluroescence for N-and E-cadherin indicated
that N-cadherin did not replace E-cadherin localization at the membrane in any of the
transformed isolates (Figures 3.17, 3.18).
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Figure 3.15 E-cadherin is unchanged in As3+ and Cd2+ transformants. A) Real time
RT-PCR analysis of E-cadherin in parent UROtsa cell line and As3+ and Cd2+ isolates
expressed as fold change normalized to β-actin. B) Western blot analysis of E-cadherin
protein in As3+ and Cd2+ isolates. PCR results represent Mean ±SEM of triplicate
determinations.
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Figure 3.16 E-cadherin is consistently expressed at the cell membrane in As3+- and
Cd2+-transformed UROtsa cells. A) Parent UROtsa cell line, B) As#3, C) As#6, D)
Cd#1, E) Cd#4. Bar= 25 µM.
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Figure 3.17 N-cadherin and E-cadherin are co-expressed at the cell membrane in
As3+-transformed UROtsa cells. N-cadherin staining in A) parent UROtsa cell line, D)
As#3, and G) As#6. E-cadherin staining in B) parent UROtsa cell line, E) As#3, and H)
As#6. N-cadherin and E-cadherin co-immunofluorescence in C) parent UROtsa cell line,
F) As#3, and I) As#6.
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Figure 3.18 N-cadherin and E-cadherin are co-expressed at the cell membrane in
Cd2+-transformed UROtsa cells. N-cadherin staining in A) parent UROtsa cell line, D)
#1, and G) Cd#4. E-cadherin staining in B) parent UROtsa cell line, E) Cd#1, and H)
Cd#4. N-cadherin and E-cadherin co-immunofluorescence in C) parent UROtsa cell line,
F) Cd#1, and I) Cd#4.
Investigation of E-cadherin in subcutaneous heterotransplant tumors yielded
similar results, with no change observed in As3+ or Cd2+ tumors (Figure 3.19). While
some induction was seen at the mRNA level in the As3+ isolates (Figure 3.19.A), a
corresponding increase in E-cadherin protein was not found (Figure 3.19.B). Tumor
immunohistochemistry showed SC tumors strongly positive at the plasma membrane for
63

E-cadherin in both As3+- and Cd2+-derived tumors (Figures 3.20 and 3.21). Levels were
similarly strong in the IP heterotransplant tumors (Figure 3.22).

Figure 3.19 E-cadherin is unchanged in subcutaneous heterotransplants. A) Real
time RT-PCR analysis of E-cadherin in parent UROtsa cells and SC tumors derived from
As3+ and Cd2+ isolates expressed as fold change normalized to β-actin. B) Western blot
analysis of E-cadherin protein in SC tumors originating from As3+ and Cd2+ isolates. PCR
results represent Mean ±SEM of triplicate determinations.
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Figure 3.20 Immunohistochemical analysis demonstrates strong E-cadherin staining
in subcutaneous heterotransplant tumors derived from As3+- transformed isolates.
E-cadherin is strongly positive in As3+ heterotransplant tumors. The staining is stronger
in the peripheral cells than the cells in the center of tumor nests. Magnification 200X A)
As#1, B) As#2, C) As#3, D) As#4, E) As#5, F) As#6.
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Figure 3.21 Immunohistochemical analysis demonstrates strong E-cadherin staining
in subcutaneous heterotransplant tumors derived from Cd2+- transformed isolates.
E-cadherin is strongly positive in heterotransplant tumor formed from all Cd2+ isolates.
The staining is stronger in the peripheral cells than the cells in the center of tumor nests.
Magnification 200X. A) Cd#1, B) Cd#2, C) Cd#3, D) Cd#4, E) Cd#5, F) Cd#6, G) Cd#7.
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Figure 3.22 E-cadherin is strongly positive in IP heterotransplant tumors. A) As#1,
B) As#3, C) Cd#1. E-Cadherin is strongly positive in the tumor cells from all 3 IP
tumors, with staining pattern similar to its subcutaneous counterparts. Magnification
200X.
The levels of N-cadherin mRNA were then compared to the human bladder
cancer cell lines J82 and TCCSUP, which have been previously characterized as
mesenchymal, and the epithelial bladder cancer RT4 (Figure 3.23). The UROtsa isolates
As#6 and Cd#5 highly expressing N-cadherin displayed levels of N-cadherin comparable
to the cell lines J82 and TCCSUP. In fact, As#6 demonstrated higher N-cadherin
expression than the human bladder cancer cell lines. However, RT-PCR with a different
set of primers which detect all splice variants of N-cadherin found that the cell lines J82
and TCCSUP contain higher levels of total N-cadherin mRNA in comparison to the
UROtsa isolates As#6 and Cd#5 (Appendix, Figure 5.1), suggesting that the human
bladder cancer cell lines utilize alternative splice variants to a greater extent.
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Figure 3.23 N-cadherin mRNA is expressed in the transformed UROtsa isolates
Cd#5 and As#6 at similar or higher levels than the mesenchymal-like bladder cancer
cell lines J82 and TCCSUP. PCR analysis of N-cadherin expressed as fold change
normalized to β-actin. PCR results represent Mean ±SEM of triplicate determinations.
To further characterize the EMT state of As3+- and Cd2+-transformed UROtsa
cells, the expression of the pro-EMT transcription factors Twist, Snail, Slug, Zeb1, and
Zeb2 were measured at the mRNA level in vitro. Expression of Twist was significantly
increased five to 15-fold in both the As3+ and Cd2+ isolates compared to parent UROtsa
cells (Figure 3.24). Snail mRNA was significantly induced in As3+-transformed isolates
relative to parent, with the exception of isolate #4, which was dramatically increased
(Figure 3.25.A). Induction was also seen at a similar level in the Cd2+-transformed
UROtsa cells (Figure 3.25B).
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Figure 3.24 Twist expression is induced in As3+ and Cd2+ isolates. A) Real time RTPCR analysis of Twist in parent UROtsa cells and A) As3+ isolates, and B) Cd2+ isolates
expressed as fold change normalized to β-actin. PCR results represent Mean ±SEM of
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001

Figure 3.25 Snail expression is induced in As3+ and Cd2+ isolates. A) Real time RTPCR analysis of Twist in parent UROtsa cells and A) As3+ isolates and B) Cd2+ isolates
expressed as fold change normalized to β-actin. PCR results represent Mean ±SEM of
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
Immunohistochemistry was performed for Snail on heterotransplant tumors
originating from the transformed isolates injected IP (Figure 3.26). The tumors deep
within the abdominal cavity (retroperitoneum or around kidney) from all 3 mice showed
moderate or moderate to strong staining of Snail (Figure 3.26.B, D, F), while the staining
of Snail is weaker in the superficial tumor in peritoneum from the same mice (Figure
3.26.A, C, E). Snail staining was strongest at the center of the tumor nests in the more
differentiated cells, while weaker at the periphery.
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Figure 3.26 Immunostaining for Snail is positive in IP tumors derived from As3+ and
Cd2+ isolates. As#1 tumor located A) at peritoneum, B) deep in abdominal cavity near
kidney. As#3 tumor located C) at peritoneum, D) deep in abdominal cavity. Cd#1 tumor
located E) at peritoneum, F) deep in abdominal cavity. The positive staining of Snail is
mainly located in the center of the tumor nests, the cells that are relatively well
differentiated with more cytoplasm. The less differentiated cells at the periphery are
almost negative for Snail or only show very weak staining. Magnification 200X.
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Vimentin expression was then considered, as it is a common marker for
mesenchymal cells. The majority of As3+ isolates showed unchanged levels of Vimentin
mRNA, with the exception of a significant decrease in As#1, and significantly increased
expression in As#5 (Figure 3.27.A). In Cd2+-transformed UROtsa cells, Vimentin was
significantly reduced in most isolates (Figure 3.27.B). Analysis of the pro-EMT
transcription factors Slug, Zeb1, and Zeb2 was also performed at the mRNA level,
though no expression was detected.
Transcription factor 4 (TCF4), is an E2-2 protein recently associated with EMT
(Sobrado et al., 2009). Interestingly, expression of TCF4 mRNA was significantly
enhanced in most As3+ isolates about 10 to 50-fold compared to parent UROtsa
cells(Figure 3.28.A). TCF4 was similarly induced in the Cd2+ transformants, to a slightly
lesser extent (Figure 3.28.B).

Figure 3.27 Vimentin expression is unaltered in As3+-transformed UROtsa cells,
while induced in Cd2+ isolates. A) Real time RT-PCR analysis of Vimentin in parent
UROtsa cells and As3+ isolates expressed as fold change normalized to β-actin. B) Real
time RT-PCR analysis of Vimentin in parent UROtsa cells and Cd2+ isolates expressed as
fold change normalized to β-actin. PCR results represent Mean ±SEM of triplicate
determinations. *p<0.05, **p<0.01, ***p<0.001
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Figure 3.28 TCF4 expression is induced in As3+ and Cd2+ isolates. A) Real time RTPCR analysis of TCF-4 in parent UROtsa cells and As3+ isolates expressed as fold change
normalized to β-actin. B) Real time RT-PCR analysis of TCF-4 in parent UROtsa cells
and Cd2+ isolates expressed as fold change normalized to β-actin. PCR results represent
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
Other EMT-associated genes were evaluated at the mRNA level. STEAP1, or six
transmembrane epithelial antigen of the prostate 1, expression was induced in Cd2+transformed UROtsa cells in vitro and in a number of SC tumors (Figure 3.29.B and D).
STEAP1 was less consistently induced in the As3+ transformants, though it was elevated
in a number of isolates in vitro and in vivo (Figure 3.29.A and C). STEAP1 is considered
to increase during EMT, though further experimental evidence is required to confirm its
role in EMT. Occludin (OCLN), a component of tight junctions, is typically decreased
during EMT (Ikenouchi, Matsuda, Furuse, & Tsukita, 2003). However, in As3+- and
Cd2+-transformed UROtsa cells, occludin was increased in many isolates in vitro and in
SC tumors (Figure 3.30). Interleukin 1 receptor antagonist, or IL1RN, is another gene
downregulated during EMT, though its expression was unchanged in As3+-transformed
UROtsa cells and significantly decreased in Cd2+ transformants (Figure 3.31).
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Figure 3.29 STEAP1 is consistently induced in Cd2+-transformed UROtsa cells in
vitro and maintained in some subcutaneous tumors. Real time RT-PCR analysis
expressed as fold change over parent normalized to β-actin in A) As3+-transformed
UROtsa cells, B) Cd2+-transformed UROtsa cells, C) SC tumors derived from As3+
transformants and D) SC tumors derived from Cd2+ transformants. Results represent
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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Figure 3.30 OCLN is consistently induced in Cd2+-transformed UROtsa cells in vitro
and maintained in select subcutaneous tumors. Real time RT-PCR analysis expressed
as fold change over parent normalized to B-actin in A) As3+-transformed UROtsa , B)
Cd2+-transformed UROtsa cells, C) SC tumors derived from As3+ transformants and D)
SC tumors derived from Cd2+ transformants. Results represent Mean ±SEM of triplicate
determinations. *p<0.05, **p<0.01, ***p<0.001
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Figure 3.31 IL1RN is varied in Cd2+-transformed UROtsa cells in vitro and in vivo.
Real time RT-PCR analysis expressed as fold change over parent normalized to B-actin
in A) As3+-transformed UROtsa cells, B) Cd2+-transformed UROtsa cells, C) SC tumors
derived from As3+ transformants and D) SC tumors derived from Cd2+ transformants.
Results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01,
***p<0.001 # indicates significantly induced #p<0.05, ##p<0.01, ###p<0.001.
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CHAPTER IV
DISCUSSION
Model Systems of Bladder Cancer in vivo
The fact that N-cadherin expression is maintained in IP, but not SC
heterotransplants suggests that tumor microenvironment may play a role in regulation of
N-cadherin and in tumor development in general. While expression of N-cadherin is
highly induced in vitro in As3+- and Cd2+-transformed UROtsa cells, the cell lines may
not have maintained their molecular characteristics upon subcutaneous injection due to
the lack of a supportive environment for progression through EMT. When injected IP,
however, the environment more closely replicates that of bladder cancer cells progressing
through EMT and metastasis, which promotes the maintenance of N-cadherin expression
in transformed UROtsa cells. Animal models for bladder cancer are scarce in comparison
to those of other cancers (Kobayashi, Owczarek, McKiernan, & Abate-Shen, 2015).
The compatibility of in vitro and animal models is an issue that is overlooked in a
number of cancers. Subcutaneous xenografts are a popular system due to the ease of cell
transplant and observation of tumor formation and growth. However, numerous clinical
trials for cancer therapeutics based on testing in SC tumor models have proven
unsuccessful (Suggitt & Bibby, 2005). In a study of colon cancer, subcutaneous tumors
demonstrate sensitivity to doxorubicin, while lung metastases developed by tail vein
injection of cancer cells are resistant. Further, expression of the genes MDR1 and pglycoprotein is enhanced in the resistant metastases compared to the subcutaneous tumors
(Dong et al., 1994). Human tumor xenografts of ovarian carcinoma also display sitespecific sensitivity to the anti-cancer drug flavone acetic acid. Intraperitoneal tumors fail
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to respond to treatment, while subcutaneous tumors show growth inhibition (Pratesi,
Manzotti, Tortoreto, Audisio, & Zunino, 1991). Interestingly, the majority of studies
involving tumor heterotransplants only observe the effects of drug treatment on tumor
formation and growth, and do not investigate whether the compounds targeted by the
drug in in vitro studies are present or altered in the animal model. Further, while some
studies compare xenograft and original tumor histology and general appearance,
molecular characterization rarely occurs. The xenograft lines UCRU-BL-12 and UCRUBL-14 are an example in which the original SC tumors were histologically similar, but
following serial implantations, differing DNA profiles developed with the emergence of
aneuploid populations (Russell et al., 1986). In an orthotopic model of bladder cancer,
expression of various integrins and MMPs is altered compared to in vitro levels in RT4
cells (Imao et al., 1999). Proper pairing between in vitro cell lines and animal models
may result in higher success rates at clinical trials and the development of biomarkers of
better predictive value for a number of cancers in addition to bladder cancer.
Some success has been found in other heterotransplant models. While
subcutaneous injection of cancer cells encapsulates the tumor and reduces the potential
for metastasis (Ahlering, Dubeau, & Jones, 1987; Kubota, 1994), injection of cells into
the peritoneum is considered to more closely replicate the environment into which
bladder, prostate, ovarian, and gastric cancers initially metastasize (Garson, Shaw, Clark,
Yao, & Vanderhyden, 2005). In fact, the bladder cancer cell line RT4 and endometrial
carcinoma line EJ shows little metastatic potential when transplanted subcutaneously.
However, when the same lines are injected via tail vein, metastatic sites develop. When
injected orthotopically to the bladder lumen, the cells develop tumors similar in histology
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and behavior to their tumors of origin (C. Zhang, Awasthi, Schwarz, & Schwarz, 2013).
The development of a renal capsule model of bladder cancer using As3+- and Cd2+transformed UROtsa cells is currently in development.
Bladder Cancer Stem Cells
Heterogeneity among cells within the transformed isolates may also contribute to
dissimilar N-cadherin expression in tumor heterotransplants versus in vitro cultures. The
UROtsa cell line and its transformants are not clonal populations. During transformation
with sodium arsenite and cadmium chloride, the cells experienced numerous phases of
massive cell death followed by regrowth from surviving cells, in which the surviving
clones were not isolated for clonal expansion. Examination of cellular heterogeneity
within each isolate had not been performed previously.
To quantitatively determine the number of cells positive for N-cadherin, flow
cytometry was performed on As3+ and Cd2+ isolates expressing low, medium, and high Ncadherin as indicated by Western blot. Results of the flow cytometry experiments found
that N-cadherin was only detected on the highest expressing isolate, As#6, and that
98.5% of the cells were positive for the protein. This is contrary to the findings from
Western blot analysis, suggesting that the levels initially observed included both
intracellular and membrane-bound N-cadherin, while the flow cytometry only detected
membrane-bound protein. Additionally, Western blot analysis with the antibody used for
flow cytometry demonstrated lower sensitivity, indicating that antibody did not detect the
N-cadherin on the the moderately-expressing isolates As#3 and Cd#1.
To further investigate the hypothesis that population heterogeneity was at play in
the As3+- and Cd2+-transformed UROtsa, the presence of tumor-initiating cells, or cancer
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stem cells, was investigated were identified within As3+- and Cd2+-transformed UROtsa
cells, suggesting that a unique subpopulation of cells in vitro are responsible for tumor
formation in vivo which may then display different molecular characterization than
observed in culture.
Microspheres were isolated by cell culture in serum-free media at low density on
low-adherence substrates. Following microsphere, or urosphere, formation, self-renewal
was confirmed by the ability to reform colonies following multiple rounds of dissociation
(data not shown). The microspheres were able to form tumors following IP injection into
nude mice, further validating their stem cell-like characteristics (data not shown).
Interestingly, the putative stem cells display significantly reduced N-cadherin
expression compared to their counterparts grown in serum-free media as evaluated by
RT-PCR, even in As3+ isolate #6, which shows the most dramatic increase in N-cadherin
compared to the parent UROtsa cell line, with 98.5% of cells positive for N-cadherin by
flow cytometry analysis. This suggests that a small subset of N-cadherin-negative cells
act as tumor-initiating cells to develop tumors in vivo, resulting in the lack of N-cadherin
expression observed.
Bladder cancer stem cells were first isolated as side populations from primary
cultures of low-grade papillary urothelial carcinoma. Side population (SP) is defined by
the ability to efflux the DNA-binding dye Hoescht 33342, and has been further
characterized as a functional marker for stem cells in numerous normal and cancerous
tissues. Another marker for bladder cancer stem cells is EMA-CD44v6+, which was
initially identified in primary cultures of low-grade papillary carcinoma. This cell
population possesses the ability for anchorage-independent colony formation, self-

79

renewal, and proliferation in vitro (Y. M. Yang & Chang, 2008). Cancer stem cells
demonstrate an enhanced ability to form tumors in vivo that replicate the original tumor.
In a study by Chan et al., CD44+ cells isolated from patient tumors display increased
ability to form tumors following SC injection into nude mice compared to CD44- cancer
cells. Further, the CD44+ cells are able to be serially transplanted for three additional
passages (Chan et al., 2009).
Cancer stem cells have been isolated from immortalized bladder cancer lines, as
well. Side populations were identified in the bladder cancer cell lines SW780, UM-UC-6,
UM-UC-6dox, 253J-BV, and HT-1197 (Jun, Peng, Zi, Wei, & Xiang, 2008). The cells
demonstrate higher colony-forming efficiency in soft agar than non-SP cells, as well as
tumor formation in subcutaneous xenografts. Expression of the ABC transporters
ABCG2 and MDR1 is significantly increased in SP cells, supporting their enhanced
efflux capability. Further, the stem cell genes Oct-4 and Bmi-1 are also elevated in the SP
cells. Stem-like cells have also been identified in SP cells from the transitional cell
carcinoma cell line T24. The side populations display increased cell growth and elevated
expression of ABCG2 expression, a marker of stem cells (Ning et al., 2009). Stem celllike compartments have been identified in heterotransplant models of bladder cancer.
Human SW780 urothelial carcinoma xenografts derived from high-grade invasive
carcinoma demonstrate basal-like CK17+ staining in cells at the tumor-stroma interface
and CK20 expression within the interior of tumor nodules which resembles staining seen
in superficial cells of the normal urothelium (X. He et al., 2009).
Aldehyde dehydrogenase 1 expression has also emerged as a marker for bladder
cancer stem cells. ALDH1A1+ cells isolated from the bladder cancer cell lines RT4,

80

HTB-9, and HTB-4 display significantly higher colony forming efficiency which is
reversed upon ALDH1A1 knockdown. Further, anchorage-independent growth is
impaired in cells with reduced ALDH1A1. ALDH1A1+ cells demonstrat increased in vivo
tumorigenicity when compared with ALDH1A1- cells, and the tumors are able to be
regenerated for at least three cycles. In human bladder cancer specimens, ALDH1A1 is
not observed in normal urothelium, though it is colocalized with tumor cells positive for
the stem cell marker CD44. In addition, ALDH1A1 status is significantly correlated with
grade and stage of bladder carcinoma, incidence of recurrence, progression, and inversely
associated with survival (Y. Su et al., 2010).
There is no consensus on bladder cancer stem cell markers (van der Horst, Bos, &
van der Pluijm, 2012). Other stem cell markers that have been utilized include VEGFR2,
CD133, Sox2, Nanog, and 67LR (Goodwin Jinesh, Willis, & Kamat, 2014; van der Horst
et al., 2012). For the purpose of identifying stem cell-like populations with the UROtsa
cell line and its transformants, the markers ALDH1A1 and CD44 were used. RT-PCR
analysis demonstrated increased expression of ALDH1A1 mRNA, though not CD44 in
urospheres compared to the transformants grown in serum-free media.
In light of the theory that N-cadherin-negative stem cells are forming
subcutaneous tumors lacking N-cadherin expression, why might these same cells create
tumors in the peritoneum that regain N-cadherin? Once again, tumor microenvironment
appears to play a role. In small cell lung cancer, tumor specimens serially propagated in
vivo lose expression of tumor-specific genes when transitioned to cell culture conditions.
This change in gene expression is not reversed upon regraftment into mice, implicating
permanent changes in cell phenotype dependent upon tumor environment (Daniel et al.,
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2009). The progression of cells through EMT to metastasis specifically is also regulated
by environment (Polyak & Weinberg, 2009). A study inducing EMT in hamster cheek
pouch carcinoma-1 cells by TGF-β found that both mesenchymal-like and epithelial-like
cells establish tumors upon subcutaneous injection. Only cells induced to undergo EMT
invade adjacent tissue, and neither cell type metastasizes to the lung. However, upon
intravenous injection only the epithelial cells develop lung metastases. Subcutaneous
injection of a mixture of both epithelial and EMT-induced cells allows invasion and lung
metastasis of epithelial cells (T. Tsuji et al., 2008). In another study utilizing prostate and
bladder cancer cell lines, tumor-initiating cells demonstrating epithelial characteristics are
able to metastasize and colonize distant sites, while cells with a mesenchymal phenotype
do not have this ability. Instead, the mesenchymal-like tumor-initiating cells show
enhanced local invasiveness when compared to the epithelial cells (Celià-Terrassa et al.,
2012). This suggests that the tumor microenvironment plays a role in cancer progression
to metastasis, and that both epithelial and mesenchymal stem cells promote cancer
progression (Polyak & Weinberg, 2009). Lastly, cancer stem cells in particular are
dependent upon their surrounding conditions for maintenance of the tumor-initiating
phenotype. Heterogeneity has been identified in stem-like populations isolated from
human bladder transitional cell carcinoma. These cells are positive for the stem cell
markers CD133, Oct-3/4, and nestin, and display increased proliferation and self-renewal.
However, upon continued culture the cells gradually loset their proliferative and
morphological characteristics and are unable to induce xenograft tumors in vivo
(Bentivegna et al., 2010). These studies suggest that N-cadherin expression in tumor
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heterotransplants requires an environment supportive of EMT, and that tumor stem cells
are also vulnerable to changes in microenvironment.
The origins of cancer stem cells remain unclear. They may arise from normal
stem or progenitor cells (Feng Li, Tiede, Massagué, & Kang, 2007), or may be derived
from differentiated cells that undergo a series of oncogenic hits to acquire self-renewal
ability and immortality (Clarke et al., 2006). However, numerous studies have found that
heavy metals can cause normal stem cells to develop a cancer stem cell-like phenotype.
Normal stem cells from human prostate acquire cancer stem cell-like characteristics when
co-cultured with transformed malignant epithelial cells. However, the phenotype is only
adapted when stem cells are cultured with arsenic-transformed, but not N-methyl-Nnitrosourea-transformed epithelial cells (Yuanyuan Xu et al., 2013). In human
keratinocyte HaCaT cells, transformation by low dose exposure to sodium arsenite
occurrs via EMT, followed by the acquisition of a malignant cancer stem cell-like
phenotype (R. Jiang et al., 2013). Human pancreatic ductal epithelial cells exposed to
chronic cadmium induce non-adherent spheroid formation and expression of the stem cell
markers OCT4 and CD44, as well as a cancer phenotype indicated by enhanced invasion
and expression of the pancreatic cancer marker S100P (Qu, Tokar, Kim, Bell, &
Waalkes, 2012). Arsenic induces EMT and malignant transformation in human bronchial
epithelial cells, as well as cancer stem cell-like characteristics, which are directly
regulated by HIF-2α (Yuan Xu et al., 2012).
Human prostate stem cells show enhanced resistance to arsenite-induced
cytotoxicity compared to the mature parental cell line, and possess hyper-adaptability to
arsenic. Further, experiments by Tokar et al. indicate that exposure to arsenic induces
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greater numbers of free-floating spheres in the parental prostate cell line than cadmium or
N-methyl-N-nitrosourea (Tokar, Qu, et al., 2010). Additional studies prove that arsenite
exposure transforms normal prostate stem cells to a malignant cancer stem cell-like
phenotype with high invasion capacity and loss of contact inhibition. The cells are also
able to form tumors when heterotransplanted that were highly aggressive, containing
immature epithelial- and mesenchymal-like cells (Tokar, Diwan, & Waalkes, 2010). As
previously mentioned, during As3+- and Cd2+-induced transformation in UROtsa cells, a
small percentage of cells survived numerous rounds of cytotoxicity. It would prove quite
interesting to isolate those cells and determine whether they contain cancer stem cell
markers, as well as the changes that occur with each round of toxicity.
Future experiments using flow cytometry to determine the expression of cancer
stem cells including ALDH1A1, CD44, and CD133 will be necessary to establish that the
microspheres indeed contain cancer stem cells. Additional studies to determine the
expression E-cadherin and N-cadherin in the cancer stem cell population are also
required, as it may be that an epithelial tumor-initiating cell population establishes IP
tumors, while an N-cadherin-expressing population develops tumors subcutaneously.
In order to address the role of microenvironment on N-cadherin expression, the
renal capsule model will be utilized. Grafting cells in the renal capsule is more efficient
than subcutaneous injections and has good predictive value of clinical response
(Baiocchi, Biffoni, Ricci-Vitiani, Pilozzi, & De Maria, 2010; Suggitt & Bibby, 2005).
Further, normal urothelial cells injected into the renal capsule are able to establish and
grow, providing an in vivo control for comparison with tumors derived from As3+- and
Cd2+-transformed UROtsa cells (Oottamasathien et al., 2006).
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Characterization of EMT in UROtsa Transformants
Since N-cadherin induction is a common sign of the epithelial-to-mesenchymal
transition, the As3+- and Cd2+-transformed UROtsa cells where characterized for
additional markers of EMT. No changes in E-cadherin were seen at the mRNA or protein
level in the transformed UROtsa cells. Further, E-cadherin did not appear to replace Ncadherin at the plasma membrane, but instead was co-expressed. While E-cadherin is
typically replaced by N-cadherin during EMT in the bladder, there are cases in which Nand E-cadherin are co-expressed, and that when this occurs, the functional properties of
N-cadherin dominate over E-cadherin. In a study by Rieger-Christ and colleagues of a
panel of bladder cancer cell lines, bladder cancers expressing high levels of E-cadherin
with no N-cadherin display little invasive capacity, and those with high N-cadherin and
reduced E-cadherin demonstrate high levels of invasiveness. Interestingly, when N- and
E-cadherin are co-expressed, invasive capacity is elevated in comparison with Ncadherin-negative cell lines, though not to the extent of cell lines with high N-cadherin
and low E-cadherin (Kimberly M Rieger-Christ et al., 2004). This implies that the promigratory property of N-cadherin overcomes the pro-epithelial effects of E-cadherin
when co-expressed, allowing EMT progression with enhanced motility and invasion. This
has also been observed in breast cancer, in which exogenous induction of N-cadherin in
the MCF-7 cell line induces higher migration rates and increased invasion in Matrigel.
When injected into nude mice, the cells co-expressing N- and E-cadherin are able to form
metastatic tumors expressing both cadherins (Hazan, Phillips, Qiao, Norton, & Aaronson,
2000).
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The pattern of progression through EMT, that is, the timing of various markers
and changes in behavior, has not been well-characterized in cancer. It is often dependent
upon the cell type observed and the agent inducing the transition. N-cadherin induction
has been correlated with tumor invasiveness, suggesting that it is upregulated late in
EMT. When compared to the epithelial human bladder cancer cell line RT4, N-cadherin
induction in As3+- and Cd2+-transformed UROtsa cells was elevated. However, the level
of induction relative to mesenchymal bladder cancers J82 and TCCSUP depended upon
the inclusion of N-cadherin splice variants, in which the human bladder cancer cell lines
appear to utilize alternative splicing. Analysis of protein expression will ultimately
determine whether N-cadherin levels in the UROtsa transformants are indeed at the
extent of that seen in J82 and TCCSUP. Elevated Vimentin expression is often associated
with late stage EMT; however in the UROtsa transformants it was not induced. Further,
transformed UROtsa cells maintained an epithelial appearance (Sens et al., 2004).
Interestingly, whereas N-cadherin demonstrates an important role for cell motility in a
study of TGF-β1-induced EMT in mammary epithelial cells, it does not affect the
morphological changes that accompany EMT. siRNA-mediated inhibition of N-cadherin
expression does not alter cell morphology, while motility is decreased, as seen in woundhealing and transwell motility assays (M. Maeda, Johnson, & Wheelock, 2005).
However, in the case of As3+- and Cd2+ transformed UROtsa cells, only a few isolates
demonstrate increased migration which do not correlate to N-cadherin expression and the
transformed cells do not have increased invasive ability (J Larson, 2012). This suggests
that while N-cadherin, Twist, and Snail are significantly elevated in transformed UROtsa
cells, the cells are in the initial states of EMT. There are no models of this type for
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bladder cancer, suggesting that the As3+- and Cd2+-transformed UROtsa cells will be of
benefit for further characterization of the patterns of gene expression and behavioral
changes in bladder cancer-associated EMT. While arsenite exposure did not induce Ncadherin expression in parent UROtsa cells, expression was elevated with increased
duration of cadmium exposure, providing a model system for the progression of EMT in
bladder. Future experiments could include analysis of other EMT markers throughout this
exposure period. The miR-200 family should also be explored in this system, as its
expression has been associated with early stages of EMT in bladder cancer.
Other markers of EMT were investigated in As3+- and Cd2+-transformed UROtsa
cells at the mRNA level, as well. The pro-mesenchymal transcription factor Twist was
significantly induced in both As3+ and Cd2+ transformants. Interestingly, phosphorylated
Twist activates transcription of TGF-β2 (Xue et al., 2012), an EMT-inducer that was
upregulated on the As3+ array and to a lesser extent on the microarray for Cd2+
transformants (Gao, Zhu, Nilsson, & Sundfeldt, 2014; Garrett et al., 2014; Medici, Hay,
& Olsen, 2008). Snail, another transcription factor promoting EMT, was also
significantly elevated. Vimentin expression was mostly unchanged in As3+-transformants,
though reduced in the majority of Cd2+ isolates. Transcription factor 4, or TCF4, was
significantly induced in As3+- and Cd2+-transformed UROtsa cells. This class 1 bHLH
factor E2-2 protein is not to be confused with T-cell-specific transcription factor 4
(TCF7L2), a factor associated with the Wnt signaling pathway. This transcription factor
is relatively unexplored in EMT, though studies have proven that it is a potent inducer of
EMT in MDCK cells (Sobrado et al., 2009). Additional transcription factors Zeb1 and
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Zeb2 were measured, though expression was undetectable or unchanged (data not
shown).
Other genes associated with EMT that were investigated included STEAP1,
OCLN, and IL1RN. STEAP1, or six-transmembrane epithelial antigen of the prostate 1,
is normally expressed at the membrane in low levels in bladder, but it is significantly
upregulated in a number of bladder cancer cell lines, including UM-UC03, TCCSUP, and
J82 (Hubert et al., 1999). In Cd2+-transformed UROtsa cells, STEAP1 was significantly
induced in vitro, and numerous isolates demonstrated elevated expression in SC tumors.
STEAP1 was less consistently induced in As3+ transformants in vitro and in vivo.
STEAP1 appears to play a role in tumor growth and intercellular communication, as
knockdown in prostate cancer and oral squamous cell carcinoma xenografts significantly
reduces tumor volume and inhibited intercellular communication in vitro (T. Yamamoto
et al., 2013). Further study of STEAP1 expression in bladder cancer is needed, as metaanalysis of gene expression data from 40 human tumor types revealed that STEAP1 is
significantly induced in 11 cancers, but bladder cancer is not one of them (Moreaux,
Kassambara, Hose, & Klein, 2012). STEAP1 is induced during progression through
EMT, though further evidence is required to confirm this association.
Occludin downregulation is observed in the epithelial-to-mesenchymal transition.
Occludin is an integral membrane protein localized at tight junctions. In a Snail-induced
model of EMT in mouse epithelial cells, Snail directly regulates occludin to decrease its
expression (Ikenouchi et al., 2003). However, occludin was not reduced in As3+ and Cd2+
transformants. In fact, expression was significantly upregulated in Cd2+-transformed
UROtsa cells in vitro, and numerous SC tumors overexpressed occludin. Evaluation of
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occludin expression at the protein level, as well as other tight junction proteins, may
indicate whether loss of tight junction functionality is occurring in this bladder cancer
model.
Interleukin 1 receptor antagonist (IL1RN) is also considered to decrease during
EMT, though evidence is limited. In Cd2+-transformed UROtsa cells, IL1RN expression
was significantly reduced, though results were varied in SC tumors. In As3+transformants, IL1RN was relatively unchanged. Interestingly, IL1RN gene
polymorphism is associated with increased risk of bladder cancer (Ahirwar, Agrahari,
Mandhani, & Mittal, 2009; Bid, Manchanda, & Mittal, 2006; Bozdoğan et al., 2014).
Further, reduced IL1RN expression is significantly correlated with aggressive bladder
cancer (Worst et al., 2014).
Other groups have determined the EMT state of numerous bladder cancer cell
lines. The TCCSUP, RT4, and J82 cell lines have been reviewed here (Table 4.1). The
J82 cell line, also known as HTB-1, is derived from a poorly differentiated invasive
transitional cell carcinoma of Stage T3 (O’Toole, Price, Ohnuki, & Unsgaard, 1978). It is
the most mesenchymal of the three lines, with strong N-cadherin expression, low levels
of E-cadherin, induced Vimentin and increased levels of the transcription factors Twist,
Snail, Slug, Zeb1, and Zeb2. TCCSUP, or HTB-5, originates from Stage 4 transitional
cell carcinoma and also contains mesenchymal characteristics with increased N-cadherin
and pro-mesenchymal transcription factors, but without loss of E-cadherin, and does not
display elevated Vimentin. RT4, or HTB-2, is the most epithelial of the three cell lines,
and was derived from transitional cell papilloma. The cell line shows little induction of
N-cadherin, strong E-cadherin, no Vimentin expression, and varied levels of pro-
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mesenchymal transcription factors (Baumgart et al., 2007). While further experiments are
required to fully compare the As3+- and Cd2+-transformed UROtsa cells to these cell
lines, they appear to be most similar to the TCCSUP cell line. Differences include the
expression of Zeb1, Zeb2, Slug, and P-cadherin. Zeb1, Zeb2, and Slug were expressed at
barely detectable levels which were unchanged in the As3+- and Cd2+-transformed
UROtsa cells (data not shown). P-cadherin was expressed, through changes in expression
were variable in the transformed cells (Appendix 5.1).
By characterizing the early and late events of EMT in bladder tumors, biomarkers
may be discovered which could earlier predict cancers with metastatic potential. It may
be that As3+- and Cd2+-induced EMT utilizes a different pathway to induce EMT, or that
TCCSUP represent a later stage. Analysis of human bladder cancer tumors from arsenicendemic regions may further establish the role of N-cadherin as a marker specific for
heavy metal-induced bladder carcinogenesis and the initial stages of EMT.
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Reference
Sandquist et al. 2015
Hänze et al. 2013
Hao et al. 2012
Wallerand et al. 2010
Sayan et al. 2009
Wu et al. 2013
Baumgart et al. 2007
Sandquist et al. 2015
Hänze et al. 2013
Yang et al. 2014
Cheng et al. 2013
Wallerand et al. 2010
Hao et al. 2012
Tran et al. 2012
Sayan et al. 2009
Choi et al. 2012
Wu et al. 2013
Baumgart et al. 2007
Sandquist et al. 2015
Hänze et al. 2013
Cheng et al. 2013
Choi et al. 2012
Wu et al. 2013
Yang et al. 2014
Baumgart et al. 2007
Sandquist et al. 2015
Yang et al. 2014
Matsui et al. 2012
Sandquist et al. 2015
Cheng et al. 2013
Tran et al. 2012
Sayan et al. 2009
Yang et al. 2014
Choi et al. 2012
Sandquist et al. 2015
Tran et al. 2012
Sayan et al. 2009
Choi et al. 2012
Sandquist et al. 2015
Yang et al. 2014
Zhang et al. 2007
Shiota et al. 2010
Sandquist et al. 2015
Cheng et al. 2013
Matsui et al. 2012
Wu et al. 2013
Sandquist et al. 2015
Mialhe et al. 2000
Sayan et al. 2009

Table 4.1 EMT characterization of transformed UROtsa cells with the human
bladder cancer cell lines TCCSUP, RT4, and J82. +++ high, ++ moderate, + low, and
– no expression.
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Regulation of N-cadherin
While the importance of N-cadherin in the epithelial-to-mesenchymal transition
has been well established, its regulation is relatively unknown. The transcription factor
Twist regulate N-cadherin promoter activity by binding at an E-box within the first intron
in prostate cancer cells (Alexander et al., 2006). Further, Twist was a top induced gene in
As3+-transformed UROtsa cells and significantly upregulated in Cd2+-transformed
isolates as indicated by microarray analysis (Garrett et al., 2014). Twist is a well-known
repressor of E-cadherin that participates in EMT; therefore, dual functionality of Twist as
both a repressor and inducer of E-cadherin and N-cadherin, respectively, is an attractive
possibility that should be explored in a wider variety of cancers.
The potential regulation of Twist by arsenite exposure has not been fully studied.
In human bronchial epithelial cells transformed by arsenite, the exposure inducs EMT,
including the expression of Twist. Further, Twist upregulation is increased in
nonmalignant cells depending upon duration of arsenite exposure, indicating metaldependent expression. However, cancer cells treated with arsenite show a different
response. Arsenic trioxide is an effective treatment for some cancers, including
hepatocellular carcinoma. In this cancer, arsenic trioxide reduces cell migration and
invasiveness and inhibits EMT by suppressing Twist (G. Z. Wang et al., 2014). In nonsmall-cell lung cancer, arsenic trioxide-induced cell death is enhanced by inhibition of
Twist (Seo et al., 2014). As such, further studies are needed to explore the divergent
mechanisms of Twist regulation by arsenite in normal and cancerous cell types. There is
less evidence for regulation of Twist by cadmium exposure. In cadmium-treated mice,
fibrotic kidney EMT is induced, accompanied by elevated Twist expression (Chakraborty
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et al., 2010). It would also be worthwhile to investigate whether Twist is regulating Ncadherin in As3+- and Cd2+-transformed UROtsa cells, considering the fact that Ecadherin expression was unaltered by heavy metal transformation. It may be the case that
Twist is acting solely as an inducer of N-cadherin expression, or that other regulatory
factors are at play.
N-cadherin expression was altered by treatment with the histone deacetylase
inhibitor MS-275, suggesting that acetylation contributes to the regulation of N-cadherin
transcription. Exposure to sodium arsenite over 5 passages in the parent UROtsa cell line
appeared to induce total levels of histone 4 acetylation at Region 2 of the N-cadherin
promoter. Further, histone acetylation state was modified at Region 2 following exposure
to MS-275, indicating that this may be a region of regulatory activity for N-cadherin
transcription. However, numerous studies have indicated that arsenic reduces histone
acetylation globally. Chu et al. found that exposure to arsenic reduces global histone
acetylation (Chu et al., 2011) and another demonstrated that As(III) and MMA(III)
reduce H4K16 acetylation in a time- and dose-dependent manner (Ge et al., 2013; Jo et
al., 2009). Experiments with UROtsa cells exposed to longer durations of sodium arsenite
and in transformed cells will confirm whether the increase in H4 acetylation at the Ncadherin promoter is a gene-specific change, or if longer exposures to arsenic are needed
to elevate histone acetylation at this region.
This work has demonstrated that N-cadherin is induced in As3+- and Cd2+transformed UROtsa cells, and that a unique early EMT signature may have potential to
act as a biomarker of bladder cancer induced by arsenic and cadmium. These studies
revealed important findings on the transcriptional regulation of N-cadherin, as well as
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histone acetylation at the promoter. N-cadherin induction was recapitulated in an
intraperitoneal animal model, though expression was not detected in tumors derived from
subcutaneous heterotransplants. Additionally, putative bladder cancer stem cells did not
express N-cadherin at high levels. These findings have broad implications in the field of
biomarker and cancer research, in which the results of in vitro studies are not successful
in clinical studies. By incorporating the factors of tumor microenvironment and cell
population in the use of animal models, a greater number of cancer biomarkers and
therapies may be successfully validated for clinical use.
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APPENDIX
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Expression of N-cadherin Splice Variants
When all splice variants of N-cadherin mRNA were targeted, N-cadherin
expression in UROtsa isolates As#5 and Cd#5 was not to the level of the bladder cancer
cell lines J82 and TCCSUP, though expression was elevated compared with the RT4 cell
line. The primers here are from Bio-Rad (qHsaCID00015189) and target splice variants
ENST00000269141, ENST00000399380, ENST00000418492, ENST00000430882, and
ENST00000413878. The splice variants detected by the Qiagen primers used for Figure
3.23 only include NM_001792, XM_005258181, and XM_005258182.

Figure 5.1 Expression of total N-cadherin splice variants in As3+- and Cd2+transformed UROtsa is lower than that of J82 and RT4 cell lines. RT-PCR analysis
of N-cadherin expression in the highest N-cadherin-expressing transformed isolates and
three human bladder cancer cell lines. Data expressed as fold change normalized to βactin. PCR results represent Mean ±SEM of triplicate determinations.
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P-cadherin Expression
P-cadherin is typically expressed in low amounts at the basal cell layer of the
urothelium with aberrant expression investigated as a bladder cancer biomarker. Further,
the expression of P-cadherin has been recently proposed as a bladder cancer stem cell
marker (Bryan, 2014).

Figure 5.2 P-cadherin expression is variable in As3+- and Cd2+-transformed UROtsa
cells. Real time RT-PCR analysis expressed as fold change over parent normalized to βactin in A) As3+ isolates and B) Cd2+ isolates. Results represent Mean ±SEM of triplicate
determinations. *p<0.05, **p<0.01, ***p<0.001.
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Eukaryotic Elongation Factor 1A2 Expression
Eukaryotic elongation factor 1A2, or eEF1A2, is a subunit of the elongation factor
1 complex that promotes translation elongation. eEF1A2 is a proto-oncogene, with
overexpression observed in a number of cancers including prostate, ovarian, and colon
cancer. Translation elongation factors have been associated with cadmium carcinogenesis
(Joseph, 2009). Commercial antibodies for eEF1A2 are not specific and also target
eEF1A2, though the Scaggiante group has developed specific antibodies (Scaggiante et
al., 2012).

Figure 5.3 eEF1A2 is induced in Cd2+ transformants in vitro. A) PCR array validation
results for eukaryotic elongation factor 1A2 in Cd2+-transformed UROtsa cells. Isolate #1
was not included in array. B) Real time RT-PCR analysis expressed as fold change over
parent confirms significant induction, though trends among isolates differ from the initial
PCR array. Annealing temperature was optimized to 66o. C) Western blot analysis for
eEF1A2 protein in Cd2+-transformed UROtsa and parent cells. *Isolate #3 is SC
heterotransplant protein. Results represent Mean ±SEM of triplicate determinations.
*p<0.05, **p<0.01, ***p<0.001
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Figure 5.4 eEF12 expression is dependent upon Cd2+ exposure in non-malignant
UROtsa cells. Real time RT-PCR analysis of eEF1A2 in parent UROtsa cells and Cd2+exposed isolates in vitro. eEF1A2 mRNA is elevated following 48 hrs 1 µM Cd2+
exposure to parent UROtsa cells. Induction was most apparent at 48 hrs. A) UROtsa cells
exposed to 0, 1, 2, and 4 µM cadmium chloride for 12, 48, and 72 hrs expressed as fold
change over time-matched non-treated control. B) Selected results from 1 µM exposure at
all time points. Data represented as fold change over parent UROtsa cells at 0 hrs
exposure. Results represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01,
***p<0.001
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Figure 5.5 eEF1A2 expression is regulated by histone acetylation state. eEF1A2
mRNA expression is induced in a dose-dependent manner following 24, 48, and 72 hr
exposure to the histone deacetylase inhibitor MS-275 in parent UROtsa cells. UROtsa
cells were only exposed to 10X MS-275 at the 24 hr time point. Expression increases
with duration of exposure between 24 and 48 hrs, followed by a decrease at 72 hrs, while
dose-dependent expression is maintained.
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NR2F1 and NR2F2 Induction in As3+- and Cd2+-transformed UROtsa Cells
Nuclear receptor subfamily 2, group F, member 1 (NRF2F1) and member 2
(NRF2F2) experiments were performed by undergraduate Andrew Millbridge.
Previously, RT-PCR analysis of 39 transitional cell carcinomas demonstrated a
significant decrease in NR2F1 expression relative to normal tissue from the same patients
(Ham, Lee, Yu, & Choi, 2008). In the bladder cancer cell line J82, retinoic acid-induced
growth inhibition and apoptosis is promoted by NR2F1 (B. Lin, Chen, Xiao, & Kumar,
2000). NR2F1 and NR2F2 have almost completely identical DNA binding domains,
though the N-terminal regions of the two proteins significantly differ (Tsai & Tsai, 1997).
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Figure 5.6 NR2F1 is induced in As3+- and Cd2+-transformed isolates and
corresponding subcutaneous heterotransplants. A) Real time RT-PCR analysis of
NR2F1 in parent UROtsa cells and As3+ and Cd2+ isolates in vitro. B) Real time RT-PCR
analysis of NR2F1 in parent UROtsa cells and As3+ and Cd2+ SC heterotransplants. C)
NR2F1 expression with 0, 1, 2, and 4 µM Cd2+ exposure for 12, 24, 48, and 72 hrs. D)
NR2F1 expression after 0, 1, 2, and 3 µM As3+ exposure for 12, 24, 48, and 72 hrs. Data
expressed as fold change relative to parent UROtsa cell line. PCR results represent Mean
±SEM of triplicate determinations.
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Figure 5.7 NR2F2 remains mostly unchanged in As3+- and Cd2+-transformed isolates
in vitro, but is reduced in subcutaneous tumors. Real time RT-PCR analysis of NR2F1
in A) As3+ transformants and B) Cd2+ isolates in vitro. C) As3+ SC tumors and D) Cd2+
SC tumors. E) Short-term As3+ exposure to parent UROtsa cells. F) Short-term Cd2+
exposure to parent UROtsa cells. Data is expressed as fold change over parent. PCR
results represent Mean ±SEM of triplicate determinations.
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Microarray Validation by Short-term As3+ Exposure
To determine genes of interest from those differentially expressed in As3+transformed UROtsa, the top five-induced genes from the microarray were selected and
changes in gene expression following short-term arsenic exposure were measured. The
genes include UDP glycosyltransferase 8 (UGT8), latrophilin 2 (LPHN2), LIM and
calponin homology domains 1 (LIMCH1), carboxypeptidase 6 (CPA6), and eukaryotic
elongation factor 1 alpha 2 (eEF1A2). eEF1A2 was the only gene significantly altered by
arsenic exposure, with results listed in a separate figure.

Figure 5.8 Microarray validation by analysis of short-term As3+ exposure. Selected
genes were the top-most induced on the As3+ array, and significantly increased on the
array of Cd2+-transformed UROtsa cells. A) UGT8, B), LPHN2, C) LIMCH1, and D)
CPA6 revealed no alteration in expression following one or three days with 6 µM sodium
arsenite. Data is expressed as fold change over parent. PCR results represent Mean ±SEM
of triplicate determinations.
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Neurotrophin-3 Expression in As3+- and Cd2+-transformed UROtsa Cells
Neurotrophin-3 (NTF3 or NT3) experiments were performed by undergraduate
Tyler Titcomb. A review of scientific literature and omics signatures for muscl-invasive
bladder cancer revealed that the neurotrophin signaling pathway was significantly
associated with the disease (Bhat et al., 2015).

Figure 5.9 NTF3 is reduced in As3+-transformed UROtsa cells at the mRNA and
protein level. A) Real time RT-PCR for neurotrophin-3 in parent and As3+ transformants
expressed as fold change over parent. PCR results represent Mean ±SEM of triplicate
determinations. B) Western blot analysis for NTF3 at 35 kDa.
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Figure 5.10 NTF3 is induced in Cd2+-transformed UROtsa cells. A) Real time RTPCR analysis for NTF3 expressed as fold change over parent. PCR results represent
Mean ±SEM of triplicate determinations. B) Western blot analysis for NTF3 at 35 kDa.
*p<0.05, **p<0.01, ***p<0.001
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Figure 5.11 Neurotrophin-3 expression is increased in As3+ and Cd2+ subcutaneous
tumors. Real time RT-PCR analysis for NTF-3 in A) As3+ SC tumors and B) Cd2+ SC
tumors expressed as fold change over parent. PCR results represent Mean ±SEM of
triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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Figure 5.12 Neurotrophin-3 expression is unchanged following short-term As3+ and
Cd2+ exposure. A) Real time RT-PCR for short-term sodium arsenite exposed parent
UROtsa cells. The 48 hr time point samples were likely misquantified. B) RT-PCR
analysis for short-term cadmium chloride exposure. Data expressed as fold change over
parent. PCR results represent Mean ±SEM of triplicate determinations. *p<0.05,
**p<0.01, ***p<0.001
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Figure 5.13 Neurotrophin-3 expression is altered by histone deacetylase inhibitor
and DNA methyltransferase inhibitor treatment. parent UROtsa cells were treated
with MS-275 for 24 hrs and 5’-azacytidine for 48 hrs. Real time RT-PCR results
expressed as fold change over parent. PCR results represent Mean ±SEM of triplicate
determinations. *p<0.05, **p<0.01, ***p<0.001
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Ephrin Receptor A4 Induction in As3+- and Cd2+-transformed UROtsa Cells
Ephrin receptor A4 (EPHA4) research was performed by undergraduate Tyler
Titcomb. EPHA4 promotes motility and invasion in pancreatic and prostate cancer
(Batson, Maccarthy-Morrogh, Archer, Tanton, & Nobes, 2014; C. Liu, Huang, Wang,
Kong, & Zhang, 2014) and is correlated with gastric cancer recurrence (Oki et al., 2008).

Figure 5.14 Ephrin Receptor A4 expression is increased in As3+ and Cd2+
transformants. Real time RT-PCR analysis in A) As3+-transformed and B) Cd2+transformed UROtsa cells expressed as fold change over parent. PCR results represent
Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001

Figure 5.15 EPHA4 expression is elevated in As3+ and Cd2+ subcutaneous tumors.
Real time RT-PCR analysis of A) As3+ SC tumors and B) Cd2+ SC tumors expressed as
fold change over parent. PCR results represent Mean ±SEM of triplicate determinations.
*p<0.05, **p<0.01, ***p<0.001
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Figure 5.16 EPHA4 expression is induced after 12 hrs As3+ exposure. A) Real time
RT-PCR analysis of parent UROtsa cells exposed to sodium arsenite. B) RT-PCR
analysis of short-term cadmium chloride. PCR results represent Mean ±SEM of triplicate
determinations.

Figure 5.17 EPHA4 is induced by MS-275, but not 5’-AZC treatment. Parent UROtsa
cells treated with 24 hrs MS-275 and 48 hrs 5’-azacytidine. Real time RT-PCR analysis
expressed as Mean ±SEM of triplicate determinations.
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Ets Variant 7 Induction in As3+- and Cd2+-transformed UROtsa Cells
Ets variant 7 (ETV7) is also known as telomere length regulation protein (Tel2).
Experiments evaluating the expression of this gene were performed by undergraduate
Andrew Millbridge. ETV7 functions as a protein to mediate Hsp90 regulation of
phosphatidylinositol-3 kinase-like kinases (PIKKs), proteins involved in DNA repair, cell
cycle control, regulation of cell growth, degradation of mRNA, and control of gene
expression (Takai, Wang, Takai, Yang, & de Lange, 2007). Hsp90 activates PIKKs via
the R2TP complex and ETV7, in which ETV7 mediates the interaction between PIKKs
and the R2TP complex. ETV7 stabilizes PIKK enzymes including mTOR, SMG1, and
ATM (Horejsí et al., 2010; Kaizuka et al., 2010). Further, ETV7 mediates the recruitment
of ATM1/Tel1 kinase to the site of double stranded DNA breaks for repair (Anderson et
al., 2008). ETV7 can also act as a transcription factor (Gu et al., 2001). Expression of
ETV7 in cancers has been little studied. ETV7 expression is elevated in breast cancer (J.
He et al., 2007) and is considered a hematopoietic oncogene (Carella et al., 2006), and
increased ETV7 protein is observed in hepatocellular carcinoma (Matos, Witzmann,
Cummings, & Schmidt, 2009). However, ETV7 is reduced in drug-resistant gastric
cancer (O. Maeda et al., 2014).
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Figure 5.18 Ets variant 1 expression is induced in As3+ and Cd2+ transformants. Real
time RT-PCR analysis of ETV7 in A) As3+-transformed UROtsa cells and B) Cd2+transformed UROtsa cells expressed as fold change normalized to β-actin. PCR results
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001

Figure 5.19 ETV7 is reduced in As3+ subcutaneous tumors, and relatively
unchanged in Cd2+ tumors. Real time RT-PCR analysis of ETV7 in A) As3+ SC tumors
and B) Cd2+ SC tumors expressed as fold change normalized to β-actin. PCR results
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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ITM2C Expression
Experiments on integral membrane protein 2c (ITM2C) expression were
performed by undergraduate Andrew Millbridge. ITM2C expressed highly in the brain
and is an inhibitor of beta-amyloid peptide production, but is known about the function of
ITM2C outside the brain.

Figure 5.20 ITM2C expression is varied in As3+ and Cd2+ transformants in vitro,
though reduced in subcutaneous tumors. Real time RT-PCR analysis of ITM2C in A)
As3+-transformed UROtsa cells, B) Cd2+-transformed UROtsa cells, C) As3+ SC tumors,
and D) Cd2+ SC tumors expressed as fold change normalized to 18S. PCR results
represent Mean ±SEM of triplicate determinations. *p<0.05, **p<0.01, ***p<0.001
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ABBREVIATIONS
67LR

67-kDa laminin receptor

8-oxo-dGTP

8-oxo-7,8-dihydrodeoxyguanosine triphosphate

ABC transporter

ATP-binding cassette transporter

ALDH1A1

aldehyde dehydrogenase 1 family, member A1

ANOVA

one-way analysis of variance

AP-1

activator protein 1

Ape-1

apurinic/apyrimidinic endonuclease 1

As3+

arsenite

ATSDR

Agency for Toxic Substances and Disease Registry

5’-AZC

5’-azacytidine

Bmi-1

B cell-specific Moloney murine leukemia virus integration site 1

BSA

bovine serum albumin

Cd2+

cadmium

CdCl2

cadmium chloride

ChIP

chromatin immunoprecipitation

CK20

keratin 20

CO2

carbon dioxide

CTBP1

c-terminal binding protein 1

DAB

3,3’-diaminobenzidine

DAPK

death-associated protein kinase

DMA(III)

dimethylarsinous acid

DMA(V)

dimethylarsinic acid
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DMEM

Dulbecco’s Modified Eagle Medium

DMT1

divalent metal transporter 1

DNA

deoxynucleic acid

E-cadherin

epithelial-cadherin

ECL

electrochemiluminescence

EDTA

Ethylenediaminetetraacetic acid

eEF1A2

eukaryotic translation elongation factor 1 alpha 2

EGF

epidermal growth factor

EMT

epithelial-mesenchymal transition

EPA

Environmental Protection Agency

EPHA4

ephrin receptor A4

ERK

extracellular signal-related kinase

ETV7

ets variant 7

FDA

Food and Drug Administration

GATA-4

GATA-binding factor 4

H3K9Me3

histone 3 lysine 9 trimethylation

H4Ac

histone 4 acetylation

HDACi

histone deacetylase inhibitor

HIF-2α

hypoxia-inducible factor 2 alpha

HRP

horseradish peroxidase

hrs

hours

Hsp

heat shock protein

IARC

International Agency for Research on Cancer
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IHC

immunohistochemistry

IL1RN

interleukin 1 receptor antagonist

IP

intraperitoneal

ITM2C

integral membrane protein 2c

Jak

Janus family tyrosine kinase LAS-AF

LCN2

lipocalin-2

MAPK

mitogen-activated protein kinase

MDR1

multi-drug resistance

µl

microliter

µM

micromolar

min

minute

miRNA

microRNA

MMA(III)

monomethylarsonous acid

MMA(V)

monomethylarsonic acid

MMP9

matrix metallopeptidase 9

mRNA

messenger RNA

MSH

Mut S homolog

MZF1

myeloid zinc finger 1

NaAsO2

sodium arsenite

N-cadherin

neuronal-cadherin

NFĸB2

nuclear factor ĸ B

NR2F1

nuclear receptor subfamily 2, group f, member 1

NR2F2

nuclear receptor subfamily 2, group f, member 2
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NRF2

nuclear factor (erythroid-derived 2)-like 2

NTF3

neurotrophin-3

NTP

National Toxicology Program

OCLN

occludin

Oct-4

octamer-binding transcription factor 4

PBS

phosphate-buffered saline

P-cadherin

placenta-cadherin

PE

phycoerythrin

PMSF

phenylmethanesulfonylfluoride

PVDF

polyvinylidene difluoride

RBPJ

recombination signal binding protein for immunoglobulin kappa J
region

RECK

reversion-inducing-cysteine-rich protein with kazal motifs

RNA

ribonucleic acid

ROS

reactive oxygen species

RT-PCR

real-time polymerase chain reaction

SEM

standard error of the mean

S100P

S100 calcium binding protein P

SC

subcutaneous

SDS

sodium dodecyl sulfate

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

siRNA

small interfering RNA

SLC1A2

solute carrier family 1 (glial high affinity glutamate transporter),
member 2
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SLC39A14

solute carrier family 39 (zinc transporter), member 14

SMAD4

SMAD family member 4

Sox2

SRY (sex-determining region Y)-box 2

Sox9

SRY (sex-determining region Y)-box 9

SPARC

secreted protein, acidic, cysteine-rich

STAT

signal transducer and activator of transcription

STEAP1

six transmembrane epithelial antigen of the prostate 1

TCF4

transcription factor 4

TGF-β

transforming growth factor beta

Tris-HCl

Tris-hydrochloride

VEGFR

vascular endothelial growth factor receptor

XPA

xeroderma pigmentosum, complementation group A

XRCC3

X-ray repair complementing defective repair in Chinese hamster
cells 3

YB-1

Y-box binding protein 1

ZIP14

zrt- and irt-like protein
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